Cryopreservation compositions and methods of use thereof
Patent Information
- Application Number
- JP2020555745
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-12-31
- Filing Date
- 2018-12-31
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2038-12-31
Smart Images

Figure 0007594441000003 
Figure 0007594441000004 
Figure 0007594441000005
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 612,552, filed December 31, 2017, which is incorporated by reference in its entirety.
[0002] Described herein are compositions and methods for the cryopreservation of mammalian cells, tissues, and organs. [Background technology]
[0003] Excessive cell death is a major barrier to the clinical use of cells, tissues, and organs obtained from living donors or cells grown in culture. This problem is particularly acute when the time between cell procurement and use is long and cells need to be stabilized during long-term storage. Broadly, the isolation process of donor cells, tissues, or organs is in itself damaging to cells, as it involves enzymatic or mechanical removal, enzymatic digestion of extracellular proteins, cell transfer between containers, centrifugation, resuspension in solution, and filtration steps. Cells can also be significantly damaged during seeding into growth chambers, a process called trituration. Routine cell manipulation in vitro is likewise a major source of cell damage. Cells in culture are routinely separated from the matrix in which they grow to allow further amplification and subsequent growth of cell numbers, to allow procedural manipulations to introduce experimental treatments such as DNA transfection, and for downstream routine measurements that require cells to be initially removed from their environment. These procedures often disrupt the integrity of the outer membrane of many cells, causing punctures and ruptures. Such physical damage to cells causes leakage of metabolic products from their cytoplasm into the surrounding extracellular space. At a physiological level, compromised plasma membrane integrity leads to excessive calcium release within the cell, reduced ATP concentrations, reduced NAD concentrations, and activation of pathways leading to necrosis and necroptosis.
[0004] Additionally, isolated cells, tissues, and organs undergo physiological damage due to interrupted circulation that places cells within the removed tissues and organs at significant risk for lack of oxygenation, free radical generation, and ischemia. These insults rapidly lead to necrosis and necroptosis within cells within the tissue, causing excessive cell death, especially in primary cells derived from animal or human tissues, ultimately leaving insufficient material for subsequent clinical use. It has also long been recognized that these necrotic cells leak their contents into neighboring cells, signaling them to die from the outside. The leakage of these cellular components, characterized as damage-associated molecular patterns (DAMPS), may activate an immunogenic response, and these molecules themselves may activate pattern recognition receptors to activate necroptosis in response to perceived inflammation in neighboring cells. Additionally, cells that survive may undergo dedifferentiation, a process in which less capable committed or differentiated cells revert to more capable differentiation cells.
[0005] Physiological damage can be partially prevented by slowing or stopping cellular metabolism during stress. One approach is to keep cells and tissues, as well as organs for transplantation, at hypothermia between isolation and later use. Another option to stop cellular metabolism and the resulting oxidative damage, available in the case of cell cultures and individual cells, is to store cells at subzero temperatures, a process called cryopreservation. However, cryopreservation itself and the freeze-thaw cycles associated with cryopreservation cause damage to cells via ice crystal formation in the immediate vicinity of the cells, and sometimes also intracellularly, again causing puncture and rupture of the external plasma membrane and internal organelles (called freeze-thaw damage). The combination of cell damage associated with isolation and cryopreservation can cause transdifferentiation of cells from one differentiation state to another cell type, or dedifferentiation of cells, thereby further complicating the subsequent use of isolated cells.
[0006] Current methods do not address the subsequent cell damage and death from these insults, resulting in excessive damage to cells, tissues, and organs. Furthermore, no solutions have been implemented to stop the subsequent necrosis. Similarly, few, if any, advances have led to improvements in cryopreservation techniques, and it is not understood which molecular pathways exactly lead to cell death during the freeze-thaw process.
[0007] Thus, there is a continuing need for methods of isolating and / or preserving tissues, cells, and organs that avoid necrosis, necroptosis, and dedifferentiation due to the physical and physiological damage that cells undergo during the isolation process. Additionally, there is a continuing need for methods of cryopreserving cells that avoid necrosis, necroptosis, and dedifferentiation due to the physical and physiological damage that cells undergo during the cryopreservation process. Finally, there is a continuing need to reduce cell plasticity, necroptosis, or necrosis due to the physical and physiological damage that cells undergo during the in vitro cell manipulation during release from tissues.
[0008] The compositions and methods disclosed herein address these needs, and use of the compositions can reduce the occurrence of necroptosis or necrosis during cryopreservation and treat, prevent, inhibit, or reduce the occurrence of cellular plasticity in a plurality of cells. Summary of the Invention
[0009] In one embodiment, disclosed herein is a composition comprising necroptosis inhibitor and Bax channel inhibitor.In another embodiment, necroptosis inhibitor comprises 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or its analogue, derivative, isomer, or pharmaceutically acceptable salt, and Bax channel inhibitor comprises 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound or its analogue, derivative, isomer, or pharmaceutically acceptable salt.
[0010] In related embodiments, the necroptosis inhibitor is selected from the group consisting of 3-p-methoxyphenyl-5,6-tetramethylenenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide compounds, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one compounds, 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin compounds, 1-([[3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, (S)-N-(1-[2-chloro- 6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide compound, methyl-thiohydantoin-tryptophan compound, (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide compound, 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea compound, or 2,2-dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of said necroptosis inhibitor compound.
[0011] In another related embodiment, the concentration of the 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or its analog, derivative, isomer, or pharma- ceutically acceptable salt is about 0.2 nM to 2 μM. In another related embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound or its analog, derivative, isomer, or pharma- ceutically acceptable salt is about 0.5 nM to 50 μM.
[0012] In another embodiment, the compositions disclosed herein further comprise nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or superoxide dismutase, or any combination thereof. In a related embodiment, the superoxide dismutase comprises manganese superoxide dismutase or zinc superoxide dismutase. In another related embodiment, the concentration of the NAD is about 5 nM to 500 μM. In another related embodiment, the concentration of the ATP is about 10 nM to 1 mM. In another related embodiment, the concentration of the cyclosporine A is about 1 nM to 1 mM. In another related embodiment, the concentration of the superoxide dismutase is about 0.001 to 100 Kunitz units (KU).
[0013] In another embodiment, the composition disclosed herein comprises about 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), about 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, about 0.05 mM nicotinamide adenine dinucleotide (NAD), about 0.01 μM adenosine triphosphate (ATP), about 0.01 μM cyclosporine A, and about 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
[0014] In a related aspect, the compositions described herein further comprise a cryoprotectant. In another related aspect, the cryoprotectant comprises DMSO, or serum, or any combination thereof.
[0015] In a related aspect, the compositions described herein further comprise a pharma- ceutically acceptable excipient or carrier.
[0016] In one aspect, disclosed herein is a method of cryopreservation, the method comprising: contacting a plurality of cells with a composition comprising a necroptosis inhibitor and a Bax channel inhibitor; and cooling the composition comprising the plurality of cells of step (a), wherein the necroptosis inhibitor comprises a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof, and the Bax channel inhibitor comprises 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof.
[0017] In one aspect, disclosed herein is a method of treating, preventing, inhibiting, or reducing cellular plasticity, or the occurrence of necroptosis or necrosis in a plurality of cells, the method comprising contacting the plurality of cells with a composition comprising a necroptosis inhibitor and a Bax channel inhibitor, wherein the necroptosis inhibitor comprises a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof, and the Bax channel inhibitor comprises 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof.
[0018] In a related embodiment, the necroptosis or necrosis is associated with aging or disease. In another related embodiment, the disease is myocardial infarction, diabetes secondary to beta cell necroptosis, cholestatic liver disease, stroke, organ ischemia, ischemia-reperfusion injury, liver disease, necrosis due to chemotherapy or radiotherapy for cancer, traumatic brain injury, necrotizing pancreatitis, pathogen-induced necroptosis, inflammation, or neurodegenerative diseases.
[0019] In a related aspect, treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, or necroptosis or necrosis includes treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in vitro or in vivo. In another related aspect, the plurality of cells includes tissue culture cells, primary cells, egg cells, tissue, or organ or a portion thereof, or any combination thereof. In another related aspect, the tissue culture cells or primary cells include stem cells, adult cells, transdifferentiated cells, dedifferentiated cells, or differentiated cells, or any combination thereof. In another related aspect, the plurality of cells includes human cells or animal cells. In another related aspect, the contacting is in vivo, ex vivo, or in vitro. In another related aspect, the in vivo or ex vivo contacting includes perfusion of an animal or a portion thereof, an organ or a portion thereof, or a tissue. In another related aspect, the perfusion is cardiac perfusion. In another related aspect, the in vitro contacting comprises immersing the plurality of cells in the composition, supplementing growth medium of the plurality of cells with the composition, perfusing the plurality of cells with the composition by non-thermal reversible electroporation, or perfusing the plurality of cells with the composition in a bioreactor.
[0020] In related aspects, the methods disclosed herein further comprise a step of physical, chemical, or thermodynamic manipulation of said plurality of cells. In related aspects, the thermodynamic manipulation comprises heating or cooling said plurality of cells. In related aspects, the cooling comprises cryopreservation or freeze-thaw cycles thereof, or a combination thereof.
[0021] In a related aspect, the methods disclosed herein prevent, inhibit or reduce necrosis or necroptic death of the plurality of cells during cryopreservation or freeze-thaw cycles thereof compared to non-contacted plurality of cells.
[0022] In a related aspect, the method disclosed herein protects the plurality of cells from physical damage during the cryopreservation or freeze-thaw cycles thereof. In another related aspect, the method enhances the proliferation capacity of the plurality of cells during cryopreservation or freeze-thaw cycles thereof compared to non-contacted cells. In another related aspect, the method prevents oxidative damage to the plurality of cells during cryopreservation or freeze-thaw cycles thereof. In another related aspect, the method prevents ischemia of the cells during cryopreservation or freeze-thaw cycles thereof. In another related aspect, the method inhibits necrotic pathway signaling. In another related aspect, the method prevents, inhibits, or reduces a change in the differentiation state of the cells, thereby stabilizing the identity of the cells compared to non-contacted cells. In another related aspect, the method induces a state of metabolic arrest in the cells. In another related aspect, the metabolic arrest comprises a reversible cessation of oxygen metabolism. In another related aspect, the method improves the viability or potential viability of the cells compared to non-contacted cells.
[0023] In another aspect, in the methods disclosed herein, the necroptosis inhibitor compound is selected from the group consisting of 3-p-methoxyphenyl-5,6-tetramethylenenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide compound, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one, 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin, methyl-thiohydantoin-tryptophan compound, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl )-2-hydroxyethanone, (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide, (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide, 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, or 2,2-dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one, or a derivative, isomer, or pharma- ceutically acceptable salt of any one of said necroptosis inhibitor compounds.
[0024] In a related aspect, in the methods disclosed herein, the concentration of the 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof, is about 0.2 nM to 2 μM, and the concentration of the 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof, is about 0.5 nM to 50 μM.
[0025] In another related embodiment, in the method disclosed herein, the composition further comprises nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese-superoxide dismutase, or zinc-superoxide dismutase, or any combination thereof. In another related embodiment, in the method disclosed herein, the concentration of the NAD is about 5 nM to 500 μM, the concentration of the ATP is about 10 nM to 1 mM, the concentration of the cyclosporine A is about 1 nM to 1 mM, and the concentration of the manganese superoxide dismutase or the zinc superoxide is about 0.001 KU to 100.0 KU.
[0026] In another related aspect, in the methods disclosed herein, the concentration of the necroptosis inhibitor 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or its analog, derivative, isomer, or pharma- ceutically acceptable salt is about 20 nM, the concentration of the Bax channel inhibitor 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound or its analog, derivative, isomer, or pharma- ceutically acceptable salt is about 5 nM, the concentration of the NAD is about 0.05 nM, the concentration of the ATP is about 0.01 μM, the concentration of the cyclosporine A is about 0.01 μM, and the concentration of the manganese superoxide dismutase or zinc superoxide is about 0.1 KU.
[0027] In a related aspect, in the methods disclosed herein, the composition further comprises a cryoprotectant. In another related aspect, the cryoprotectant comprises DMSO, or serum, or any combination thereof.
[0028] In a related aspect, in the methods disclosed herein, the composition further comprises a pharma- ceutically acceptable carrier or excipient.
[0029] The following drawings form part of the specification and are included to further demonstrate certain embodiments of the present disclosure, and the methods disclosed in the specification may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Brief description of the drawings]
[0030] [Figure 1a] Figures 1A-1C. Tissue dissection and cell manipulation result in reactive oxygen species (ROS) (detection of Nox1), apoptosis (detection of CASP3), and necrosis (detection of staining with PI and / or Annexin V) in several cell types. Figure 1A shows ROS (detection of Nox1) following dissection and cell manipulation of mouse cortical neuron tissue. While dissection produced very little ROS (mock), ROS production increased several-fold in tissue immediately after dissection (fresh), but the inclusion of a cryopreservation solution (solution) reduced ROS levels. [Figure 1b] Figure 1B shows that apoptosis was enhanced after dissection (Fresh) compared to non-manipulated tissue (Mock), but to a lesser extent than ROS generation (Figure 1A) or necrosis (Figure 1C), while inclusion of cryopreservation solution (+Solution) reduced this back to baseline levels. [Figure 1c] Figure 1C shows that necrosis was enhanced after tissue dissection and cell manipulation (Fresh) compared to no tissue manipulation (Mock), and this effect was almost completely removed by inclusion of cryopreservation solution (+ Solution). (For Figures 1A-1C, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 2a]Figures 2A-2C. Freezing / thawing cells significantly increases ROS, apoptosis, and necrosis markers over time in many cell types. Figure 2A shows that freezing / thawing neurons generated ROS (detection of Nox1) compared to pre-freezing tissue (mock), and this effect was almost completely abolished by the inclusion of cryopreservation solution (+ solution). [Figure 2b] FIG. 2B shows that apoptosis was slightly enhanced after freezing / thawing (Frozen) compared to pre-freezing tissue (Mock), and this effect was reduced by inclusion of cryopreservation solution during the freezing process (+Solution). [Figure 2c] Figure 2C shows that necrosis was significantly enhanced after freezing / thawing (frozen) of cells compared to pre-frozen tissue (mock), and this effect was nearly abolished by inclusion of cryopreservation solution (+ solution). (For Figures 2A-2C solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) CypD - Cyclophilin D [Diagram 3]Freezing / thawing cycles of cells results in loss of stem cell identity as judged by CHAT1 levels in motor neurons. Cryoprotectants in solutions used to freeze cells maintained motor neuron identity as judged by CHAT1 levels. Figure 3 shows that stem cells (motor neuron progenitor cells) cultured to express CHAT1 (fresh) and then frozen in solutions containing 0.01 μM cyspA (cyclosporine A), or 20 nM Nec1, or 5 nM iMAC2 maintained CHAT1 levels compared to stem cells frozen without the presence of these compounds that exhibit very low levels of CHAT1+ cells after freezing (frozen). As shown here, cyspA, Nec1, and IMAC2 each provided cryoprotection to stem cells upon freezing and maintained cellular properties. [Figure 4a] 4A-4B. In one embodiment of the cryopreservation solution, the viability of fresh versus frozen cells was analyzed by maintaining dissected cells (hippocampal neurons). FIG. 4A shows that the cryopreservation solution disclosed herein, by itself, was able to increase the viability of cells freshly dissected as well as cells frozen in an embodiment of the cryopreservation solution and then thawed. (Solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase. ) Symbols in FIG. 4A and throughout the figure: "Fresh" represents cells freshly dissected, "Fresh + solution" represents cells freshly dissected in composition solution, "Frozen" represents frozen / thawed cells, and "Frozen + solution" represents frozen / thawed cells in composition solution. [Figure 4b]FIG. 4B shows that metabolic arrest of cells (hippocampal neurons) enhances cell viability, and the percentage of viability provided by the various components of the cryopreservation solution is shown. Neuronal cell viability was measured after 7 days in vitro. No cryopreservation solution was added to the vehicle, but Necrostatin 1 (Nec1), Cyclosporine A (CspA), iMAC2 (iMAC2), or a combination of these three reagents (combination) were introduced to the cells prior to the freeze / thaw process. In one embodiment (combination + perfusion), the three-reagent cryopreservation solution was perfused briefly into live pregnant mice just before the pups were separated from their dams, and then hippocampal neurons were isolated from the pups at E18 (embryonic day 18). The concentrations of the various components are those used in FIG. 4A. [Diagram 5] The freezing process used herein avoids the supercooling effect that damages cells. Figure 5 shows a comparison of temperature change over time during freezing in any embodiment of the cryopreservation solution disclosed herein (EVERGREEN™ media solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, 0.1 Kunitz units manganese superoxide dismutase, also known as EVERLAST™) versus conventional media. Note the absence of an initial downward spike in temperature that occurs with conventional media. [Figure 6a] Figures 6A-6D. Viability and proliferation: fresh vs. frozen cell viability over time: neurons and adipose (fat tissue) stem cells. Figure 6A shows that cortical neuronal cell viability was maintained when cells were suspended in a cryopreservation solution embodiment disclosed herein immediately after dissection (fresh+solution) or when dissected in a cryopreservation solution embodiment disclosed herein and then frozen (frozen+solution). [Figure 6b]Figure 6B shows the time course of neuronal viability over time (days) after plating cells exposed to these frozen and non-frozen conditions, compared with the same cells exposed to 10% DMSO prior to freezing (Frozen) or freshly dissected cells without cryoprotectant (Fresh). [Figure 6c] FIG. 6C shows that viability of adipose (adipose tissue-derived) stem cells was maintained when the cells were suspended immediately after dissection in an embodiment of the cryopreservation solution disclosed herein (Fresh+Solution) or when dissected and then frozen in an embodiment of the cryopreservation solution disclosed herein (Frozen+Solution). [Figure 6d] Figure 6D shows the time course of adipose stem cell viability over time (days) after plating cells exposed to these freezing and non-freezing conditions. The inclusion of cryopreservation solution was compared to the same cells exposed to 10% DMSO prior to freezing (frozen) or to freshly dissected cells without cryoprotectant (fresh). (For Figures 6A-6D, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 7a] Figures 7A-7B. Apoptosis after dissection and freezing / thawing with cryopreservation solution. Figure 7A shows a comparison of the effect of cryoprotectants on early apoptotic cells (primary liver hepatocytes) from fresh and frozen cells suspended in an embodiment of a cryopreservation solution disclosed herein compared to cells suspended in the absence of such solution (mock). Frozen cells not treated with cryopreservation solution (mock) were suspended in 10% DMSO prior to freezing. Caspase 3 (green) labels cells in an early apoptotic state in culture. [Figure 7b]Figure 7B shows the number of apoptotic cells as defined by Annexin V labeling in fresh or frozen and thawed cells suspended in an embodiment of a cryopreservation solution disclosed herein, or in the absence of such a solution (mock). (For Figures 7A-7B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 8a] 8A-8B. Necrosis of cortical neuronal cells suspended in embodiments of the cryopreservation solutions disclosed herein after dissection and freeze / thaw. Figure 8A shows a comparison of the presence of necrotic cells from solutions of fresh and frozen cells suspended in embodiments of the cryopreservation solutions disclosed herein compared to cells suspended in the absence of such solution. Anti-cyclophilin antibodies label cells in an early apoptotic state in culture. [Figure 8b] FIG. 8B shows the percentage of necrotic cells following dissections made in an embodiment of a cryopreservation solution or in the absence of such a solution. (For FIGS. 8A-8B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 9a]Figures 9A-9B. Generation of reactive oxygen species (ROS) (Nox1 as a marker) after dissection and freezing / thawing of cortical neuronal tissue. Figure 9A shows Nox1 staining in fresh (dissected in saline only, not frozen) neurons, fresh neurons dissected in cryopreservation solution (fresh + solution), neurons frozen in suspension in an embodiment of the cryopreservation solution disclosed herein and then thawed (frozen + solution), or neurons similarly treated in the presence of a conventional cryoprotectant (10% DMSO, dimethylsulfoxide) (frozen). Fresh or thawed neurons were plated, post-adhesion fixed, and labeled for 4 hours. NADPH oxidase (Nox1) labels intracellular ROS. NeuN staining of cortical neurons (but not glia). [Figure 9b] FIG. 9B shows ROS generation (Nox1 intensity) in cortical neuronal tissue only immediately after dissection (fresh, blue bar), fresh cortical neuronal tissue dissected in suspension of an embodiment of a cryopreservation solution disclosed herein (fresh+solution, red bar), frozen cells suspended in an embodiment of a cryopreservation solution disclosed herein and then thawed (frozen+solution, yellow bar), or cells frozen in the presence of 10% DMSO and then thawed (green bar). (For Figures 9A-9B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 µM adenosine triphosphate (ATP), 0.01 µM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 10a] 10A-10B. Motor neuron markers of neuronal cell lineage are preserved to a greater extent when using conventional cryoprotectants (10% DMSO) compared to the composition solution. Figure 10A shows micrographs of neurons before and after freezing in the presence or absence of the cryopreservation solution disclosed herein (10% DMSO only). [Figure 10b]FIG. 10B shows motor neuron cell identity (as measured by the presence of CHAT1-positive, S100-positive immunofluorescence signals) in cells before and after freezing in a conventional cryopreservation solution (10% DMSO) and an embodiment of a cryopreservation solution disclosed herein (the "post-freeze composition"). (For FIGS. 10A-10B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 11a] 11A-11B. Primary mouse liver cells (hepatocytes) show similar physiological properties after freezing / thawing in the presence of composition solution compared to freshly dissected tissue. Figure 11A shows a comparison of fresh and frozen liver cells (blue staining) incubated in the presence or absence (fresh, not frozen) of the cryopreservation solution disclosed herein, and not stimulated (-galactosamine) or stimulated with galactosamine for a short time before fixation, stained with antibody-conjugated uridine (red staining) as a general measure of galactosamine-induced transcription. [Figure 11b]FIG. 11B shows a comparison of hepatocyte transcriptional activity in fresh and frozen cells suspended in an embodiment of a cryopreservation solution disclosed herein, where hepatocyte activity is similar after freezing / thawing when cells are maintained in the presence of a cryopreservation solution disclosed herein. Bars are a measure of antibody-bound uridine staining (arbitrary units). (For FIGS. 11A-11B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 12] Several analogs of necrostatin function similarly in cryoprotective effects after freezing / thawing. Figure 12 shows the effect of cryopreservation solutions containing various necrostatins. The presence of necrostatins (Nec1 (red bars), Nec2 (yellow bars), Nec3 (green bars)) significantly enhanced the viability of primary mouse cortical neuronal cells compared to control cells (vehicle, blue bars) cryopreserved in conventional cryoprotectant (10% DMSO). The concentration of various necrostatins was 20 nM, while other components of the "solution" remained the same, i.e., 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 µM adenosine triphosphate (ATP), 0.01 µM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase. [Figure 13a] 13A-13B. The necrotic pathway is halted by the composition solution. Figure 13A shows images of primary mouse hepatocytes (hepatocytes) before and after freezing in a conventional cryopreservation solution (10% DMSO) and an embodiment of a cryopreservation solution disclosed herein ("composition freezing"). The cells here are stained with an antibody that recognizes HMBG1 (green) as a marker of necroptosis. [Figure 13b]FIG. 13B shows that necroptosis markers were significantly inhibited in cell suspensions of cryopreservation solutions embodiments disclosed herein compared to 10% DMSO ("DMSO frozen"). (The cryopreservation solution used here was 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) [Figure 14]TNF-α production in necroptosis-induced THP-1 cells was significantly reduced by cryopreservation solution, EVERGREEN™ vehicle solution (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; also known as EVERLAST™). Results of ELISA assay of TNF-α after culturing THP-1 cells and inducing them to produce proinflammatory cytokines with necrotic cell lysate combined with lipopolysaccharide (LPS). TNF-α levels (pg / mL) after mock stimulation (1-3), after LPS stimulation only (4-6), after LPS stimulation in the presence of 10% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol (7-9), after LPS stimulation in the presence of 100% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol (10-12). (*) Significant differences (p<0.01) between mock (1-3) and LPS alone (4-6), and between LPS alone (4-6) and LPS + 10% EVERGREEN™ vehicle solution (7-9). (**) Significant difference (p<0.001) between LPS alone (4-6) and LPS + 100% EVERGREEN™ vehicle solution (10-12). [Figure 15]IL-6 production in necroptosis-induced THP-1 cells was significantly reduced by cryopreservation solution (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; also known as EVERLAST™). ELISA assay results for IL-6 after THP-1 cells were cultured and induced to produce proinflammatory cytokines with necrotic cell lysate in combination with lipopolysaccharide (LPS). IL-6 levels (pg / mL) were measured after (1-3) mock stimulation, (4-6) LPS stimulation only, (7-9) LPS stimulation in the presence of 10% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol, and (10-12) LPS stimulation in the presence of 100% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol. (*) Significant differences (p<0.01) between mock (1-3) and LPS alone (4-6), and between LPS alone (4-6) and LPS + 10% EVERGREEN™ vehicle solution (7-9). (**) Significant differences (p<0.001) between LPS alone (4-6) and LPS + 100% EVERGREEN™ vehicle solution (10-12). [Figure 16]A cryopreservation solution (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; also known as EVERLAST™) provided significant consistency in cytokine release measurements. Variability was calculated by averaging the percent error for each (triplicate) experiment (n=3) and expressing the variability for each group (stimulated with 10% EVERGREEN™, 100% EVERGREEN™) as a percentage of the variability for the mock (control) stimulated group, which results in an approximately 100% increase in variability without the EVERGREEN™ vehicle solution (at both the 10% and 100% levels). [Figure 17] Cryopreservation solution (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; also known as EVERLAST™) conferred significantly more consistent post-freeze / thaw neuronal viability compared to DMSO. Primary mouse hippocampal neurons were frozen using EVERGREEN™ vehicle solution compared to dimethyl sulfoxide (DMSO), and post-thaw survival was measured and plotted. Five independent experiments were measured. [Figure 18]Cryopreservation solution EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; also known as EVERLAST™) resulted in significant consistency in neuronal survival after freezing / thawing. The percent variation was calculated by calculating the mean value (n=5) for each experiment and expressing the individual measurements for each group as a ratio to the mean value of the individual values. From this, the percent deviation was calculated and expressed as a ratio to the mean. This represents an approximately 300% increase in variability when the EVERGREEN™ vehicle solution is not used. [Figure 19A] Figures 19A-19H. Hippocampal neurons display indistinguishable physiological properties before (immediately after dissection) and after freeze / thaw using cryopreservation solution (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; also known as EVERLAST™). Patch clamp of neurons from embryonic days 17-19 shows current and voltage profiles from both spontaneous and evoked neuronal activity. Figure 19A shows hippocampal neurons from a mouse brain immediately after dissection and shows whole-cell current clamp (at resting membrane potential) recordings demonstrating network activity in the culture. Vertical bars represent 20 millivolt (mV) magnitudes and horizontal bars represent 2 seconds (s) of recording. [Figure 19B]Figure 19B shows hippocampal neurons from a freshly dissected mouse brain after freeze / thaw using EVERGREEN™ vehicle solution, and whole-cell current clamp (at resting membrane potential) recordings show network activity in the cultures. Vertical bars represent 20 millivolt (mV) magnitudes, and horizontal bars represent 2 seconds (s) of recording. [Figure 19C] Figure 19C shows the cumulative frequency over a 5 minute recording interval of current clamp data showing the mean frequency of action potential discharges. Values are the mean + SE (standard error) of at least four independent experiments and are not statistically significantly different (p>0.7, Student's t-test) either before or after freeze / thawing using EVERGREEN™ vehicle solution. [Figure 19D] Figure 19D shows hippocampal neurons from a mouse brain immediately after dissection, and whole-cell voltage clamp (at approximately 60 mV) recordings demonstrate network activity in the culture. Vertical bars represent a magnitude of 200 picoamps (pA), and horizontal bars represent 2 seconds (s) of recording. [Figure 19E] Figure 19E shows hippocampal neurons from a mouse brain immediately after dissection after freeze / thawing using EVERGREEN™ vehicle solution, and whole-cell voltage clamp (at approximately 60 mV) recordings show network activity in the cultures. Vertical bars represent a magnitude of 200 picoamps (pA), and horizontal bars represent 2 seconds (s) of recording. [Figure 19F] Figure 19F shows the cumulative frequency over a 5 minute recording interval of voltage clamp data showing the mean frequency of action potential discharges. Values are the mean + SE (standard error) of at least four independent experiments and are not statistically significantly different (p>0.8) either before or after freeze / thawing using EVERGREEN™ vehicle solution. [Figure 19G]Figure 19G shows evoked presynaptic action potentials (lower trace) and postsynaptic excitatory synaptic responses (upper trace) shown in current clamp mode at resting potential (shown on the left of the schematic as black circles at the end of the axon from the lower presynaptic neuron) from two adjacent coupled hippocampal neurons both before (left trace, immediately after dissection) and after (right trace) freeze / thaw using EVERGREEN™ vehicle solution. Here, excitatory postsynaptic currents (EPSCs) are not statistically different between treatments (actual values, 71+ / -23 pA before, vs. 76+ / -28 pA after). Representative traces from n=19-22 neurons, at least three independent experiments for each treatment (p>0.7, Student's t-test). Vertical bars represent the magnitude of 20 picoamperes (pA) of a current-clamped neuron (presynaptic, lower trace) and 20 millivolts (mV) of the excitatory synaptic response (postsynaptic, upper trace), and horizontal bars represent 20 milliseconds (ms) of the recording. [Figure 19H] Figure 19H shows the amplitude ratio of presynaptic (pre / post) evoked action potentials to postsynaptic responses of 19 hippocampal neurons (measured in part G) both before (closed circles) and after (open circles) freeze / thawing with EVERGREEN™ vehicle solution. The mean ratios of neurons before and after freeze / thawing with EVERGREEN™ vehicle solution are not statistically different (p>0.7, Student's t-test) (mean value 71+ / -23 pA before freeze / thaw vs. mean value 76+ / -28 pA after freeze / thaw). X values correspond to the number of neurons for each treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] In the following detailed description, many specific details are described in order to provide a complete understanding of the compositions and methods presented herein.In other instances, well-known methods, procedures, and components are not described in detail in order not to obscure the compositions and methods disclosed herein and the resulting inhibition of necrosis and necroptosis, suppression of ischemia and oxidative damage, improvement of cell viability, cell proliferation potential, and stabilization of cell identity.
[0032] In one embodiment, disclosed herein is a composition for cryopreservation of mammalian cells, tissues, organs and parts thereof, comprising a necroptosis inhibitor and a Bax channel inhibitor.In another embodiment, disclosed herein is a method for cryopreservation of mammalian cells, tissues and organs, comprising: (a) contacting the cells, tissues or organs or parts thereof with a composition comprising a necroptosis inhibitor and a Bax channel inhibitor; and (b) cooling the composition comprising the cells, tissues or organs or parts thereof.In a further embodiment, disclosed herein is a method for suppressing, preventing or avoiding cell necrosis resulting from physical and physiological damage to cells during in vitro cell manipulation during release from tissue and during tissue cryopreservation and freeze-thaw cycles.
[0033] composition In one embodiment, disclosed herein is a composition comprising a necroptosis inhibitor and a Bax channel inhibitor. Those skilled in the art will understand that necroptosis can include any form of active necrosis (death of living cells or tissues). In some embodiments, necrosis includes cell membrane and organelle destruction, cell swelling and mitochondrial damage, followed by cell lysis and accompanied by inflammatory response. In some embodiments, necroptosis includes responses to inflammatory signals and stresses, particularly from tissues. In some embodiments, necroptosis includes regulated necrosis.
[0034] In one embodiment, necroptosis includes active or programmed necrosis (cell death). In another embodiment, necroptosis includes necrotic cell death dependent on receptor-linked protein kinase-1 (RIPK1). In another embodiment, necroptosis includes necrotic cell death dependent on receptor-linked protein kinase-3 (RIPK3). In another embodiment, necroptosis includes a regulated caspase-independent cell death mechanism that results in morphological characteristics resembling necrosis. In some embodiments, activation of the TNF receptor leads to activation of RIPK1 and subsequent recruitment of RIPK3 to form the necrosome. In another embodiment, necroptosis includes a non-apoptotic cell death pathway.
[0035] In one embodiment, the necroptosis inhibitor comprises a compound that inhibits all forms of active necrosis. In another embodiment, the necroptosis inhibitor comprises a compound that inhibits all forms of necroptosis. In another embodiment, the necroptosis inhibitor comprises a compound that inhibits all forms of necroptosis. In another embodiment, the necroptosis inhibitor comprises an inhibitor of receptor-coupled protein kinase-1 (RIPK1)-dependent necrotic cell death. In another embodiment, the necroptosis inhibitor comprises an inhibitor of receptor-coupled protein kinase-3 (RIPK3)-dependent necrotic cell death. In another embodiment, the necroptosis inhibitor comprises an inhibitor of a regulated caspase-independent cell death mechanism that results in morphological characteristics resembling necrosis.
[0036] Without wishing to be bound by theory, it has been shown that the activity of receptor-associated protein kinase (RIPK) is important for cells to undergo necroptosis. In addition, the activity of RIP kinase is also known to promote the release of inflammatory mediators such as TNFα from cells, which may induce inflammation and further promote necroptosis. In one embodiment, the necroptosis inhibitor comprises a RIPK inhibitor. In another embodiment, the necroptosis inhibitor comprises a RIP1 inhibitor. In another embodiment, the necroptosis inhibitor comprises a RIP3 inhibitor.
[0037] In one embodiment, the necroptosis inhibitor comprises the compound 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione (Necrostatin-1s), or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof. In another embodiment, the structure of Necrostatin-1s is represented by Formula 1: [ka]
[0038] As used herein, "5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione", "5-((7-chloro-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione", "7-Cl-O-MH-Trp", "Necrostatin-1s", "Nec-1s", "Nec-1 stable", "RIPK1 inhibitor II", "receptor-interacting protein 1 inhibitor II", "necrosis inhibitor IV", and "7N-1" may all be used interchangeably with the same meaning and quality.
[0039] One of ordinary skill in the art will appreciate that the term "analog" can encompass any compound that has a similar structure to another, but differs from it with respect to certain moieties, such as functional groups or substructures. The term "analog" is used interchangeably with "analog compound."
[0040] One of ordinary skill in the art will understand that the term "Necrostatin-1s analog" can encompass compounds that have a similar structure to Necrostatin-1s, but differ therefrom with respect to certain components, such as the replacement of one atom or group of atoms or functional group or substructure with another atom or group of atoms or functional group or substructure. In another embodiment, the necroptosis inhibitor is any necrostatin-1s analog known in the art.
[0041] In another embodiment, the necroptosis inhibitor comprises a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione (Necrostatin-1s) compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor comprises a 3-p-methoxyphenyl-5,6-tetramethylenenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide (Nec-5) compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor comprises a (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one compound (Nec-7) or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor compound comprises the compound 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin (necrostatin-1; Nec-1) or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof. In one embodiment, Nec-1 is represented by the structure of formula II: [ka]
[0042] In another embodiment, the necroptosis inhibitor compound comprises a methyl-thiohydantoin-tryptophan compound, or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor compound comprises a 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compound (Nec-3a), or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor compound comprises a (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide compound (Nec-4), or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor compound comprises the (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide compound (necrosulfonamide), or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof. In another embodiment, the necroptosis inhibitor compound comprises the 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea compound (RIP1 inhibitor III), or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof.
[0043] In another embodiment, the necroptosis inhibitor compound is selected from the group consisting of 3-p-methoxyphenyl-5,6-tetramethylenenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide (Nec-5) compound, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one compound (Nec-7), 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin compound (Nec-1), methyl-thiohydantoin-tryptophan compound, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compound (Nec-3a), (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide compound (Nec-4), (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide compound (necrosulfonamide), 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea compound (RIP1 inhibitor III), 2,2-dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one (GSK'963), or an analog, derivative, isomer, or pharma- ceutically acceptable salt of any one of said necroptosis inhibitor compounds.
[0044] In another embodiment, the necroptosis inhibitor comprises a 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone (Necrostatin-1) compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof. As used herein, the terms "5-(1H-indol-3-ylmethyl)-3-methyl-2-thio-hydantoin", "methylthiohydantoin-DL-tryptophan", or "MTH-DL-tryptophan", "MTH-Trp", "RIP1 inhibitor I", "necrosome inhibitor I", "receptor-interacting protein 1 inhibitor I", "necrosis inhibitor II", or "Nec-1" may all be used interchangeably with the same meaning and quality.
[0045] One of ordinary skill in the art will understand that the term "Necrostatin-1 analog" can encompass compounds that have a similar structure to Necrostatin-1, but that differ therefrom with respect to certain components, such as the replacement of one atom or group of atoms or functional group or substructure with another atom or group of atoms or functional group or substructure. Several necrostatin-1 analogs have been described in the art and are contemplated herein (e.g., U.S. Pat. No. 8,324,262, columns 1-31 and 51-52; U.S. Pat. No. 8,658,689, columns 2-31; U.S. Pat. No. 9,108,955, columns 2-31 and U.S. Pat. No. 9,499,521, columns 2-5, 12-20 and 49-57; U.S. Patent Application Publication No. 2005 / 0119260, paragraphs
[0008] to
[0103] ; U.S. Patent Application Publication No. 2013 / 0158024, paragraphs
[0009] to
[0166] ; U.S. Patent Application Publication No. 2010 / 0190836, paragraphs
[0009] to [01 68], PCT Patent Application Publication No. 2012 / 0122889, paragraphs
[0008] to
[0266] , and PCT Patent Application Publication No. 2014 / 0024657, paragraphs
[0008] to
[0423] and
[0447] , PCT Patent Application Publication No. WO2014 / 152182, pages 2-4, 6-9, 11-14, and PCT Patent Application Publication No. WO2016 / 094846, pages 2-4, 13-19, and 39-50, and EPO Patent Application Publication No. EP3017825, paragraphs
[0009] ,
[0021] , and
[0025] , all of which are incorporated herein by reference in their entireties).
[0046] In another embodiment, the necroptosis inhibitor is any necrostatin-1 analog or necrostatin-1s inhibitor known in the art.
[0047] In another embodiment, the necroptosis inhibitor is 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione (Nec-1s), 3-p-methoxyphenyl-5,6-tetramethylenethieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide (Nec-5) compound, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2- Imino-3-(thiazol-2-yl)thiazolidin-4-one compounds (Nec-7), 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin compounds (Nec-1), methyl-thiohydantoin-tryptophan compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-2- (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide compound (Nec-4), (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide compound (necrosulfonamide), 1-(4-(4-aminophenyl)-2-hydroxyethanone compound (Nec-3a), (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide compound (Nec-5), (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide compound (necrosulfonamide), 2,2-Dimethyl-1-(5(S)-phenyl-4,5-dihydropyrazol-1-yl)-propan-1-one compound (GSK'963), or an analog, derivative, isomer, or pharma- ceutically acceptable salt of any one of said necroptosis inhibitors.
[0048] Without wishing to be bound by theory, mitochondria are believed to be central orchestrators of both apoptosis and regulated necrosis. In some embodiments, mitochondria become dysfunctional during regulated necrosis in a process called "maladaptation," in which mitochondria swell, lose the ability to generate ATP, and then burst. In some embodiments, the maladaptation process is driven in part by the opening of the mitochondrial permeability transition pore (MPTP), which in turn activates Bax and Bak protein-mediated signaling. In some embodiments, Bax (Bcl-2-associated X protein) is a protein found primarily in the cytosol. In some embodiments, at the onset of necrosis, Bax undergoes a conformational shift and becomes associated with the mitochondrial membrane, forming a multimeric pore in the mitochondrial membrane.
[0049] Several Bax channel inhibitors have been described in the art and are contemplated herein (see, for example, PCT Patent Application Publication No. WO2014 / 110476, pages 18-40, and EPO Patent Application Publication No. EP1094063, pages 5-14, all of which are incorporated herein by reference in their entirety). In another embodiment, the Bax channel inhibitor is any Bax channel inhibitor known in the art. In another embodiment, the Bax channel inhibitor comprises an analog, derivative, isomer, or pharma- ceutically acceptable salt of a Bax channel inhibitor.
[0050] In one embodiment, the Bax channel inhibitor comprises the compound 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof.
[0051] In an embodiment, the compositions disclosed herein comprise a necroptosis inhibitor comprising a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analogue, derivative, isomer, or a pharmaceutically acceptable salt thereof, and a Bax channel inhibitor comprising a 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or a pharmaceutically acceptable salt thereof.
[0052] In one embodiment, the composition comprises 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 3-p-methoxyphenyl-5,6-tetramethylenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide compound, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl) Thiazolidin-4-one compounds, 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5 -cyano-1-methyl-1H-pyrrole-2-carboxamide compound, methyl-thiohydantoin-tryptophan compound, (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide compound, or 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea compound, or 2,2-dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of said necroptosis inhibitor compound, and a Bax channel inhibitor or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof.
[0053] In another embodiment, the composition comprises 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 3-p-methoxyphenyl-5,6-tetramethylenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide compound, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one Compounds, 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carbo
[0036] In one embodiment, the compound is selected from the group consisting of 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea compounds, 2,2-dimethyl-1-(5(S)-phenyl-4, 5-dihydro-pyrazol-1-yl)-propan-1-one compounds, or analogs, derivatives, isomers, or pharmaceutically acceptable salts thereof; and Bax channel inhibitors comprising 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compounds, or analogs, derivatives, isomers, or pharmaceutically acceptable salts thereof.
[0054] One of ordinary skill in the art will understand that the term "isomer" can encompass optical isomers and analogs, structural isomers and analogs, conformational isomers and analogs, etc. Optical isomers are also known as enantiomers, and in one embodiment can include one of two stereoisomers that are non-superimposable (non-identical) mirror images of one another.
[0055] In one embodiment, the isomer comprises an optical isomer of the necroptosis inhibitor compound. It will be understood by those skilled in the art that the necroptosis inhibitor compound disclosed herein may contain at least one chiral center. Thus, the necroptosis inhibitor compound used in the compositions and methods disclosed herein may exist in optically active form or racemate. Some compounds may also exhibit polymorphism. It should be understood that in one embodiment, the necroptosis inhibitor compound may encompass any racemate, optically active form, polymorph, or stereoisomer, or mixture thereof, that has properties useful in the methods of cryopreservation herein. In another embodiment, any racemate, optically active form, polymorph, or stereoisomer, or mixture thereof, of the necroptosis inhibitor compound described herein may have properties useful in the methods of treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity disclosed herein.
[0056] Those skilled in the art will understand that the term "enantiomer" can include compounds that have a center of chirality and are one of two stereoisomers that are perfect mirror images that cannot be superimposed on each other. As is known in the art, enantiomers differ from each other in their ability to rotate plane polarized light and can be classified as S- or R-enantiomers according to the CIP (Cahn-Ingold-Prelog) rules. The S- and R-configurations refer to the three-dimensional orientation of the four substituents around the chiral central carbon atom.
[0057] In one embodiment, the necroptosis inhibitor compound is a pure (R) isomer. In another embodiment, the necroptosis inhibitor compound is a pure (S) isomer. In another embodiment, the necroptosis inhibitor compound comprises a mixture of (R) and (S) isomers. In another embodiment, the necroptosis inhibitor compound is a racemic mixture comprising equal amounts of (R) and (S) isomers. Methods for preparing optically active forms (e.g., by resolution of racemic forms by recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation using chiral stationary phases) are well known in the art.
[0058] In one embodiment, the Bax channel inhibitor compound is the pure (R) isomer. In another embodiment, the Bax channel inhibitor compound is the pure (S) isomer. In another embodiment, the Bax channel inhibitor compound comprises a mixture of (R) and (S) isomers. In another embodiment, the Bax channel inhibitor compound is a racemic mixture comprising equal amounts of (R) and (S) isomers. Methods for preparing optically active forms (e.g., by resolution of racemic forms by recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation using chiral stationary phases) are well known in the art.
[0059] Those skilled in the art will understand that the term "tautomer" may include compounds that are produced by the phenomenon that a proton of one atom of a molecule shifts to another atom, thereby forming a structural isomer of the original compound. See Jerry March, Advanced Organic Chemistry: Reactions, Mechanisms and Structures, Fourth Edition, John Wiley & Sons, pages 69-74 (1992). Tautomers also refer to one of two or more structural isomers that exist in equilibrium and are easily converted from one isomer to another. Examples include keto-enol tautomers such as acetone / propen-2-ol, cyclic chain tautomers such as glucose / 2,3,4,5,6-pentahydroxy-hexanal, aromatic tautomers, and the like. The compounds described herein may have one or more tautomers and thus include various isomers. All such isomeric forms of these compounds are expressly included in the compositions disclosed herein.
[0060] Those skilled in the art will understand that the term "derivative" may include any pharma- ceutically acceptable or non-pharma-ceutically acceptable derivative suitable for use in the processes disclosed herein. Those skilled in the art will understand that non-pharma-ceutically acceptable derivatives may be used to prepare compounds and derivatives suitable for pharmaceutical use. In one embodiment, the derivatives used or prepared in the compositions disclosed herein are pharma-ceutically acceptable derivatives.
[0061] Those skilled in the art will appreciate that the term "pharmaceutically acceptable salts" may encompass those salts that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic response, etc., and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For a review of suitable salts, see Berge et al., J.Pharm.Sci., 1977,66,1-19.
[0062] Typically, pharma-ceutically acceptable salts can be easily prepared by using a desired acid or base as needed. The salts can be precipitated from solution and collected by filtration or can be recovered by evaporation of the solvent. The salts can also be prepared in situ during the final isolation and purification of the compounds of the compositions disclosed herein, or separately by reacting the free base with a suitable organic acid.
[0063] Salts may include acid addition salts resulting from the reaction of an acid with a basic nitrogen atom. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds disclosed herein. Suitable addition salts are formed from acids which form non-toxic salts, examples of which include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, cyclohexylsulfamate, dihydrochloride, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glutarate, glycolate, glycollylarsanilate, hemisulfate, hexylresorcinate, hydrabamine, The salts are hydrobromide, hydrochloride, hydrogen phosphate, hydroiodide, hydroxynaphthoate, iodide, isethionate, itaconate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyl bromide, methyl nitrate, methyl sulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmate, palmitate, pantothenate, phosphate / diphosphate, pyruvate, polygalacturonate, propionate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, theoclate, tosylate, triethiodide, trifluoroacetate and valerate. In some embodiments, salts prepared with the compositions disclosed herein include succinate, glutarate, and hemisulfate salts.
[0064] In one embodiment, the concentration of the necroptosis inhibitor contained in the composition disclosed herein comprises a range of about 0.2 nM to about 2 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 0.2 nM to about 0.5 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 0.5 nM to about 5 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 5 nM to about 50 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 50 nM to about 500 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 50 nM to about 100 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 100 nM to about 200 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 200 nM to about 300 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 300 nM to about 400 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 400 nM to about 500 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 500 nM to about 1 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 500 nM to about 600 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 600 nM to about 700 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 700 nM to about 800 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 800 nM to about 900 nM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 900 nM to about 1 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1 μM to about 2 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1 μM to about 1.1 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1 μM to about 1.2 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.2 μM to about 1.3 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.3 μM to about 1.4 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.4 μM to about 1.5 μM.In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.5 μM to about 1.6 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.6 μM to about 1.7 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.7 μM to about 1.8 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.8 μM to about 1.9 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 1.9 μM to about 2.0 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 2 μM to about 200 μM. In another embodiment, the concentration of the necroptosis inhibitor comprises a range of about 200 μM to about 500 μM.
[0065] In one embodiment, the final concentration of the necroptosis inhibitor contained in the composition disclosed herein is about 0.2 nM. In another embodiment, the final concentration of the necroptosis inhibitor is about 2.0 nM. In another embodiment, the final concentration of the necroptosis inhibitor is about 20 nM. In another embodiment, the final concentration of the necroptosis inhibitor is about 200 nM. In another embodiment, the final concentration of the necroptosis inhibitor is about 2 μM.
[0066] In one embodiment, the concentration of the necrostatin-1s compound contained in the composition disclosed herein comprises a range of about 0.2 nM to about 2 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 0.2 nM to about 0.5 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 0.5 nM to about 5 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 5 nM to about 50 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 50 nM to about 500 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 50 nM to about 100 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 100 nM to about 200 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 200 nM to about 300 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 300 nM to about 400 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 400 nM to about 500 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 500 nM to about 1 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 500 nM to about 600 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 600 nM to about 700 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 700 nM to about 800 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 800 nM to about 900 nM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 900 nM to about 1 μM. In another embodiment, the concentration of the Necrostatin-1s compound comprises a range of about 1 μM to about 2 μM. In another embodiment, the concentration of the Necrostatin-1s compound comprises a range of about 1 μM to about 1.1 μM. In another embodiment, the concentration of the Necrostatin-1s compound comprises a range of about 1 μM to about 1.2 μM. In another embodiment, the concentration of the Necrostatin-1s compound comprises a range of about 1.2 μM to about 1.3 μM. In another embodiment, the concentration of the Necrostatin-1s compound comprises a range of about 1.3 μM to about 1.4 μM.In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 1.4 μM to about 1.5 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 1.5 μM to about 1.6 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 1.6 μM to about 1.7 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 1.7 μM to about 1.8 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 1.8 μM to about 1.9 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 1.9 μM to about 2.0 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 2 μM to about 200 μM. In another embodiment, the concentration of the necrostatin-1s compound comprises a range of about 200 μM to about 500 μM.
[0067] In one embodiment, the final concentration of the necrostatin-1s compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of necrostatin-1s in the compositions disclosed herein is about 0.2 nM. In another embodiment, the final concentration of the necrostatin-1s compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of necrostatin-1s in the compositions disclosed herein is about 2.0 nM. In another embodiment, the final concentration of the necrostatin-1s compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of necrostatin-1s in the compositions disclosed herein is about 20 nM. In another embodiment, the final concentration of the necrostatin-1s compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of necrostatin-1s in the compositions disclosed herein is about 200 nM. In another embodiment, the final concentration of the necrostatin-1s compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt of necrostatin-1s in the compositions disclosed herein is about 2 μM.
[0068] In one embodiment, the concentration of the Bax channel inhibitor included in the composition disclosed herein comprises a range of about 0.5 nM to about 50 μM. In another embodiment, the concentration of the Bax channel inhibitor comprises a range of about 0.5 nM to about 5 nM. In another embodiment, the concentration of the Bax channel inhibitor comprises a range of about 5 nM to about 50 nM. In another embodiment, the concentration of the Bax channel inhibitor comprises a range of about 50 nM to about 500 nM. In another embodiment, the concentration of the Bax channel inhibitor comprises a range of about 500 nM to about 5 μM. In another embodiment, the concentration of the Bax channel inhibitor comprises a range of about 5 μM to about 50 μM.
[0069] In one embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof in the compositions disclosed herein comprises a range of about 0.5 nM to about 50 μM. In another embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof in the compositions disclosed herein comprises a range of about 0.5 nM to about 5 nM. In another embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof in the compositions disclosed herein comprises a range of about 5 nM to about 50 nM. In another embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof, in the compositions disclosed herein, comprises a range of about 50 nM to about 500 nM. In another embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof, in the compositions disclosed herein, comprises a range of about 500 nM to about 5 μM. In another embodiment, the concentration of the 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof, in the compositions disclosed herein, comprises a range of about 5 μM to about 50 μM.
[0070] In one embodiment, the final concentration of the Bax channel inhibitor in the composition disclosed herein is about 0.5 nM. In another embodiment, the final concentration of the Bax channel inhibitor in the composition disclosed herein is about 5 nM. In another embodiment, the final concentration of the Bax channel inhibitor in the composition disclosed herein is about 50 nM. In another embodiment, the final concentration of the Bax channel inhibitor in the composition disclosed herein is about 500 nM. In another embodiment, the final concentration of the Bax channel inhibitor in the composition disclosed herein is about 5 μM. In another embodiment, the final concentration of the Bax channel inhibitor in the composition disclosed herein is about 50 μM.
[0071] In one embodiment, the final concentration of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or analogs, derivatives, isomers, or pharmaceutically acceptable salts in the compositions disclosed herein is about 0.5 nM. In another embodiment, the final concentration of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or analogs, derivatives, isomers, or pharmaceutically acceptable salts in the compositions disclosed herein is about 5 nM. In another embodiment, the final concentration of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or analogs, derivatives, isomers, or pharmaceutically acceptable salts in the compositions disclosed herein is about 50 nM. In another embodiment, the final concentration of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or analogs, derivatives, isomers, or pharmaceutically acceptable salts in the compositions disclosed herein is about 500 nM. In another embodiment, the final concentration of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or analogs, derivatives, isomers, or pharmaceutically acceptable salts in the compositions disclosed herein is about 5 μM. In another embodiment, the final concentration of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or analogs, derivatives, isomers, or pharmaceutically acceptable salts in the compositions disclosed herein is about 50 μM.
[0072] In some embodiments, the compositions disclosed herein further comprise adenosine triphosphate (ATP). Without wishing to be bound by theory, in some embodiments, it is believed that loss of cellular ATP and reactive oxygen species (both as a result of mitochondrial maladaptive processes) are generated, which are harmful to cells and further drive necrotic signaling. Additionally, in some embodiments, ATP depletion leads to increased Ca production by mitochondria. 2+This allows the uptake of ATP, resulting in the opening of the permeability transition pore (PTP), which in some embodiments leads to the release of cytochrome C, mitochondrial swelling and death. Thus, in some embodiments, the ATP in the composition reverses or reduces the loss of ATP due to cell membrane destruction caused by cell dissociation from tissue and cryopreservation, thereby relieving the pressure of necroptosis. In additional embodiments, the ATP in the composition preserves mitochondrial function by minimizing the slowdown of mitochondrial respiration, and also helps to replenish lost cellular metabolic products lost in the process of destroying cells.
[0073] In one embodiment, the ATP is present at a concentration of about 10 nM to about 1 mM. In another embodiment, the ATP is present at a concentration of about 10 nM to about 100 nM. In another embodiment, the ATP is present at a concentration of about 100 nM to about 1 μM. In another embodiment, the ATP is present at a concentration of about 1 μM to about 10 μM. In another embodiment, the ATP is present at a concentration of about 10 μM to about 100 μM. In another embodiment, the ATP is present at a concentration of about 100 μM to about 100 mM.
[0074] In some embodiments, the final concentration of ATP in the compositions disclosed herein is about 10 nM. In another embodiment, the final concentration of ATP in the compositions disclosed herein is about 100 nM. In another embodiment, the final concentration of ATP in the compositions disclosed herein is about 1 μM. In another embodiment, the final concentration of ATP in the compositions disclosed herein is about 10 μM. In another embodiment, the final concentration of ATP in the compositions disclosed herein is about 100 μM. In another embodiment, the final concentration of ATP in the compositions disclosed herein is about 1 mM.
[0075] In some embodiments, the compositions disclosed herein further comprise a nicotinamide adenine dinucleotide (NAD) compound. Without wishing to be bound by theory, in some embodiments, cellular loss of NAD is believed to further contribute to cell necrosis through various mechanisms, including, in some embodiments, inhibition of glycolysis and reduced activity of the sirtuin family of proteins. An additional effect of NAD depletion is, in some embodiments, a reduction in NADP / NADPH production. In some embodiments, NADPH provides a reducing equivalent for biosynthetic reactions and protects against ROS (reactive oxygen species) necroptosis-inducing signals. Thus, in some embodiments, low NAD levels are believed to be a trigger for the activation of several mediators of necroptotic cell death. Thus, in some embodiments, the NAD in the composition reverses or mitigates the loss of NAD due to cell membrane disruption, in some embodiments, caused by cell dissociation from tissue or cryopreservation. In other embodiments, the NAD in the composition suppresses necroptosis signaling.
[0076] In some embodiments, supplementation of NAD prevents the decline of NAD levels in the hippocampus and the subsequent release of cathepsin B from lysosomes after ischemia / reperfusion injury. In some embodiments, high intracellular NADDH causes CaMKII to phosphorylate and inactivate caspase-2, which has multiple effects including preventing necrosis by keeping caspase-2 in its pro-caspase inactive enzyme form. In some embodiments, NAD also influences the differentiation state of cells, maintaining their active state to prevent dedifferentiation and self-renewal programs. Thus, in some embodiments, the addition of NAD to the freezing composition prevents excessive cell death and loss by ensuring regeneration of chemical reduction pathways. Furthermore, with sufficient cellular NADPH derived from NAD, caspases remain sufficiently low in activity to avoid cell death (necrosis) while preventing regression along the differentiation pathway. Thus, in some embodiments, NAD in the composition inhibits cell differentiation and, in some embodiments, supports the maintenance of cell identity in cells experiencing stress due to membrane disruption caused by cell dissociation from tissue or cryopreservation.
[0077] In one embodiment, the NAD is present at a concentration of about 5 nM to about 500 μM. In another embodiment, the NAD is present at a concentration of about 5 nM to about 50 nM. In another embodiment, the NAD is present at a concentration of about 5 nM to about 50 nM. In another embodiment, the NAD is present at a concentration of about 50 nM to about 500 nM. In another embodiment, the NAD is present at a concentration of about 500 nM to about 5 μM. In another embodiment, the NAD is present at a concentration of about 5 μM to about 50 μM. In another embodiment, the NAD is present at a concentration of about 50 μM to about 500 μM.
[0078] In one embodiment, the final concentration of NAD in the composition disclosed herein is about 5 nM. In another embodiment, the final concentration of NAD in the composition disclosed herein is about 50 nM. In another embodiment, the final concentration of NAD in the composition disclosed herein is about 500 nM. In another embodiment, the final concentration of NAD in the composition disclosed herein is about 5 μM. In another embodiment, the final concentration of NAD in the composition disclosed herein is about 50 μM. In another embodiment, the final concentration of NAD in the composition disclosed herein is about 500 μM.
[0079] In some embodiments, the compositions disclosed herein further comprise cyclosporin A. In one embodiment, the compositions disclosed herein further comprise an inhibitor of cyclophilin D (CypD). In another embodiment, the inhibitor is cyclosporin A. In some embodiments, cyclosporin A is an immunosuppressant that prevents mitochondrial swelling following calcium activation, and in some embodiments, has been shown to protect against reactive oxygen species-induced necrotic death in many cell types, including the liver. In some embodiments, cyclophilin D (cypD) is a peptidyl-prolyl isomerase that resides in the mitochondrial matrix and controls MPTP, and in some embodiments, is central to early determination of mitochondrial dysfunction leading to necrotic cell death.
[0080] Without wishing to be bound by theory, in some embodiments, it is believed that cyclophilin D regulates regulated necrosis or necroptosis by controlling the open state of MPTP, and its inhibition by cyclosporin A has been shown to be protective against calcium- and oxidative stress-induced death of hepatocytes. In some embodiments, CypD inhibition also provides protection from ischemic injury, and in some embodiments, can rescue some aspects of neurodegenerative diseases, including muscular dystrophies, and in hepatotoxicity models. Thus, necroptosis resulting from ischemia-reperfusion injury is, in some embodiments, sensitive to CypD activity, which is directly related to this form of injury-mediated cell death.
[0081] In one embodiment, the cyclosporine A is present at a concentration of about 1 nM to about 1 mM. In another embodiment, the cyclosporine A is present at a concentration of about 1 nM to about 10 nM. In another embodiment, the cyclosporine A is present at a concentration of about 10 nM to about 100 nM. In another embodiment, the cyclosporine A is present at a concentration of about 100 nM to about 1 μM. In another embodiment, the cyclosporine A is present at a concentration of about 1 μM to about 10 μM. In another embodiment, the cyclosporine A is present at a concentration of about 10 μM to about 100 μM. In another embodiment, the cyclosporine A is present at a concentration of about 100 μM to about 1 mM.
[0082] In one embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 1 nM. In another embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 10 nM. In another embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 100 nM. In another embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 1 μM. In another embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 10 μM. In another embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 100 μM. In another embodiment, the final concentration of cyclosporine A in the composition disclosed herein is about 1 mM.
[0083] In some embodiments, the compositions disclosed herein further comprise a superoxide dismutase. In one embodiment, the superoxide dismutase is Cu-Zn superoxide dismutase. In another embodiment, the superoxide dismutase is Fe-Mn superoxide dismutase. In one embodiment, the superoxide dismutase is a mammalian superoxide dismutase. In another embodiment, the superoxide dismutase is a human superoxide dismutase. There are three types of superoxide dismutase in mammals, type 1, called SOD-1, is a cytosolic type, type 2, called SOD2, is a mitochondrial type, and type 3, called SOD3, is an extracellular type.
[0084] Without wishing to be bound by theory, in some embodiments, it is believed that removal of cells, tissues, or organs from their natural environment results in disruption of metabolic nutrition and normal oxygenation causing ischemia, which in some embodiments, in turn causes calcium overload and the production of excess reactive oxygen species (ROS), such as peroxides, superoxides, and hydroxyl radicals. In some embodiments, high levels of reactive oxygen damage cellular structures, causing oxidative stress, thereby in some embodiments, inducing necrosis. Thus, in some embodiments, the superoxide dismutase in the composition that neutralizes ischemia-induced reactive oxygen species may be, in one embodiment, a natural superoxide dismutase purified from human or animal tissue. In another embodiment, the superoxide dismutase is a recombinant superoxide dismutase, expressed in human, animal, or bacterial cell culture and then purified. Methods for expressing and purifying recombinant proteins are well known in the art. See, for example, Sambrook et al. (MOLECULAR CLONING: A LABORATORY MANUAL (Sambrook et al, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989); Ausubel et al. (CURRENT PROTOCOLS IN MOLECULAR BIOLOGY Ausubel et al., eds., John Wiley & Sons, New York, 1987).
[0085] In one embodiment, the superoxide dismutase is present at a concentration of about 0.001 Kunitz Units (KU) to about 100 KU. In another embodiment, the superoxide dismutase is present at a concentration of about 0.001 KU to about 0.01 KU. In another embodiment, the superoxide dismutase is present at a concentration of about 0.01 KU to about 0.1 KU. In another embodiment, the superoxide dismutase is present at a concentration of about 0.1 KU to about 1 KU. In another embodiment, the superoxide dismutase is present at a concentration of about 1 KU to about 10 KU. In another embodiment, the superoxide dismutase is present at a concentration of about 10 KU to about 100 KU.
[0086] In one embodiment, the final concentration of superoxide dismutase in the composition disclosed herein is about 0.001 Kunitz units (KU). In another embodiment, the final concentration of superoxide dismutase in the composition disclosed herein is about 0.01 KU. In another embodiment, the final concentration of superoxide in the composition disclosed herein is about 0.1 KU. In another embodiment, the final concentration of superoxide dismutase in the composition disclosed herein is about 1 KU. In another embodiment, the final concentration of superoxide dismutase in the composition disclosed herein is about 10 KU. In another embodiment, the final concentration of superoxide dismutase in the composition disclosed herein is about 100 KU.
[0087] As used herein, the term "Kunitz unit" refers to a unit of enzyme activity defined in the Kunitz assay (Kunitz M., 1950 Crystalline Deoxyribonuclease II. Digestion of Thymus Nucleic Acid The Kinetics of Reaction: J. Gen. Physiol., 33 363-377).
[0088] In some embodiments, the compositions disclosed herein comprise a necroptosis inhibitor, such as a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, and a Bax channel inhibitor, such as a 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, and further comprise nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof.
[0089] In some embodiments, the compositions disclosed herein comprise a necrosis inhibitor, a Bax channel inhibitor, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof.
[0090] In some embodiments, the compositions disclosed herein comprise 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione) compound, 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase, or zinc superoxide dismutase. In some embodiments, the compositions disclosed herein comprise 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione) compound, 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase, zinc superoxide dismutase, or a combination thereof.
[0091] In another embodiment, the composition disclosed herein comprises 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, 0.1 Kunitz Units of manganese superoxide dismutase or zinc superoxide dismutase (EVERGREEN™ Media Solution or EVERLAST™).
[0092] In a further embodiment, the composition disclosed herein further comprises a cryoprotectant.Those skilled in the art will understand that the term "cryoprotectant" can include a chemical that minimizes ice crystal formation in a cell sample (e.g., cell culture, tissue or organ) when the sample is cooled to a temperature below freezing, and does not substantially damage the sample after warming, compared to the cooling effect without this agent. Suitable cryoprotectants can be either natural or synthetic, and include polyvinylpyrrolidone, dextran, maltodextrin, 2,3-butanediol, hydroxyethyl starch, polyethylene glycol, propylene glycol, glucose, glycerol, dimethylformamide, sucrose, raffinose, maltodextrin, stachyose, lactose, starch, trehalose, glucose, cyclodextrin (e.g., α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, or mixtures thereof), mannitol, dextrose, carboxymethylcellulose, serum (either human, animal, or synthetic alternatives, including supplements essential for proper nutritional support), and other commonly used agents (pH stabilizers, sugars, amino acids, stabilizers, antibiotics, etc.), or combinations thereof, each of which represents an independent embodiment of the compositions disclosed herein. Several additional cryoprotectants are known in the art (see, e.g., U.S. Pat. No. 8,440,390, which is incorporated herein by reference in its entirety).
[0093] In some embodiments, the amount of cryoprotectant in the compositions disclosed herein includes the range of 1% to 15% by weight. In some embodiments, the amount is about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight. In some embodiments, the amount is at least about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight. In some embodiments, the amount is at most about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight.
[0094] In some embodiments, the cryoprotectant of the composition comprises dimethyl sulfoxide (DMSO). In some embodiments, the amount of DMSO in the compositions disclosed herein comprises a range of 1% to 15% by weight. In some embodiments, the amount of DMSO in the compositions disclosed herein comprises a range of 3% to 10% by weight. In some embodiments, the amount is about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight. In some embodiments, the amount is at least about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight. In some embodiments, the amount is at most about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight.
[0095] In some embodiments, the cryoprotectant of the composition comprises serum. In one embodiment, the serum comprises a synthetic serum substitute, which may contain supplements essential for proper nutritional support of cells, tissues, and / or human serum, animal serum, or organs. In another embodiment, the serum comprises human serum. In another embodiment, the serum comprises animal serum. In another embodiment, the serum comprises a synthetic serum substitute. In another embodiment, the synthetic serum substitute comprises supplements essential for proper nutritional support of cells, tissues, and / or organs.
[0096] In some embodiments, the amount of serum in the compositions disclosed herein comprises a range of 1% to 15% by weight. In some embodiments, the amount of serum in the compositions disclosed herein comprises a range of 3% to 10% by weight. In some embodiments, the amount is about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight. In some embodiments, the amount is at least about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight. In some embodiments, the amount is at most about 1%, 2%, 3%, 4%, 5%, about 6%, 7%, 8%, 9%, 10%, or 15% by weight.
[0097] In some embodiments, the compositions disclosed herein further comprise a cryoprotectant, including DMSO or serum, or any combination thereof. In some embodiments, the compositions disclosed herein further comprise any cryoprotectant known in the art.
[0098] In some embodiments, the compositions disclosed herein further comprise a pharma- ceutically acceptable excipient or carrier.
[0099] In one embodiment, the compositions disclosed herein comprise a necrosis inhibitor, a Bax channel inhibitor, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, and manganese or zinc superoxide dismutase, a cryoprotectant, and a pharma- ceutically acceptable carrier or excipient.
[0100] In another embodiment, the compositions disclosed herein comprise 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase or zinc superoxide dismutase, a cryoprotectant, and a pharma- ceutically acceptable carrier or excipient.
[0101] In another embodiment, the composition disclosed herein comprises 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, 0.1 Kunitz Units of manganese superoxide dismutase or zinc superoxide dismutase, a cryoprotectant, and a pharma- ceutically acceptable carrier or excipient.
[0102] Those skilled in the art will understand that the term "pharmacologically acceptable" with respect to carriers and excipients can encompass those compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio.
[0103] Those skilled in the art will understand that the term "pharmaceutically acceptable carrier" can include pharma- ceutically acceptable materials, compositions, or vehicles, such as liquid or solid fillers, diluents, or solvent encapsulants, involved in the transport or transfer of a compound of interest from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that can serve as pharma- ceutically acceptable carriers and s include sugars such as lactose, glucose, sucrose, and the like; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate, and the like; surfactants such as polysorbate 80 (i.e., Tween 80); powdered tragacanth, malt, gelatin, talc; s such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, soybean oil, and the like; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, pH buffers, polyesters, polycarbonates, and / or polyanhydrides, and other non-toxic compatible substances used in pharmaceutical formulations.
[0104] In some embodiments, the compositions disclosed herein include one or more pharmaceutical excipients or other additives. Such excipients or additives may include one or more stabilizing polyols, such as higher polysaccharides / polymers (to promote controlled release), magnesium stearate, leucine or trileucine (as a lubricant), and phospholipids or surfactants.
[0105] Those skilled in the art will understand that the term "pharmaceutical acceptable excipient" includes any component other than the compounds described herein (e.g., a vehicle that can suspend or dissolve active compounds) and has the properties of being non-toxic and non-inflammatory to patients. Excipients can include, for example, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (coloring agents), emollients, emulsifiers, fillers (diluents), film-forming or coating agents, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, or hydration water. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0106] Those skilled in the art will appreciate that the term "pH-stabilizer" can include buffers and pH-altering agents. Suitable pH stabilizers include trisodium phosphate, anhydrous sodium carbonate, glycine, citric acid, and the like, or mixtures thereof. Flavoring agents are well known to those skilled in the art and include, but are not limited to, fruity flavors. Frescofort Flavour Permaseal, Grenadine Flavour Permaseal, Tutti Frutti Flavour, or combinations thereof.
[0107] Those skilled in the art will understand that the term "sugar" may include all known mono-, di- and / or oligosaccharides common in the pharmaceutical industry, such as sucrose (saccharose), glucose, fructose, maltose, lactose, galactose and / or starch hydrolysates. An embodiment of the composition of the present invention is particularly characterized by containing sucrose as the sugar.
[0108] Those skilled in the art will understand that the term "amino acid" can include one of the naturally occurring amino carboxylic acids found in proteins, or a synthetic amino acid not found in nature.
[0109] Those skilled in the art will appreciate that the term "antibiotic" can encompass pharmacologically active substances for the treatment of microbial infections, including broad-spectrum antibiotics that are effective against many families of microorganisms, and narrow-spectrum antibiotics that are particularly effective against individual microbial species.
[0110] In one embodiment, the term "about" refers to a deviation of 0.0001-5% from a given number or range of numbers. In one embodiment, the term "about" refers to a deviation of 1-10% from a given number or range of numbers. In one embodiment, the term "about" refers to a deviation of up to 25% from a given number or range of numbers.
[0111] In some embodiments, the term "comprising" or grammatical forms thereof, as known in the pharmaceutical industry, refers to the inclusion of the indicated active agent, such as a compound disclosed herein, as well as the inclusion of other active agents, and pharma- ceutically acceptable carriers, excipients, emollients, stabilizers, and the like. In some embodiments, the term "consisting essentially of" refers to a composition in which the active agent is the indicated active agent only, but other compounds may be included to stabilize, preserve, etc. the formulation, but which are not directly involved in the processing effect of the indicated active agent. In some embodiments, the term "consisting essentially of" may refer to an ingredient that exerts a processing effect via a mechanism different from that of the indicated active agent. In some embodiments, the term "consisting essentially of" may refer to an ingredient that exerts a processing effect and belongs to a class of compounds different from that of the indicated active agent. In some embodiments, the term "consisting essentially of" may refer to an ingredient that exerts a processing effect by acting via a mechanism of action different from that disclosed herein and belongs to a class of compounds different from the indicated active agent. In some embodiments, the term "consisting essentially of" may refer to an ingredient that facilitates the release of the active agent. In some embodiments, the term "consisting essentially of" refers to a composition comprising an active agent and a pharma- ceutically acceptable carrier or excipient.
[0112] In some embodiments, the compositions disclosed herein consist essentially of a necroptosis inhibitor, a Bax channel inhibitor, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof. In some embodiments, the compositions disclosed herein consist essentially of a necroptosis inhibitor, a Bax channel inhibitor, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof.
[0113] In some embodiments, the compositions disclosed herein consist essentially of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione) compound, 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, and manganese superoxide dismutase or zinc superoxide dismutase. In some embodiments, the compositions disclosed herein consist essentially of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione) compound, 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof.
[0114] In another embodiment, the composition disclosed herein consists essentially of 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
[0115] In some embodiments, the compositions disclosed herein consist of a necroptosis inhibitor, a Bax channel inhibitor, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof. In some embodiments, the compositions disclosed herein consist of a necroptosis inhibitor, a Bax channel inhibitor, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof.
[0116] In some embodiments, the compositions disclosed herein consist of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione) compound, 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase, or zinc superoxide dismutase. In some embodiments, the compositions disclosed herein consist of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione) compound, 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or manganese or zinc superoxide dismutase, or any combination thereof.
[0117] In another embodiment, the composition disclosed herein consists of 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
[0118] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
[0119] Throughout this application, various embodiments disclosed herein may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the compositions disclosed herein. Thus, the description of a range should be considered to specifically disclose all possible subranges and individual numerical values within that range. For example, the description of a range such as 1-6 should be considered to specifically disclose subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, and the individual numerical values within that range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
[0120] Whenever a numerical range is given herein, it is meant to include any recited numbers (fractional or integer) within the range given. The expressions "range between" a first recited number and a second recited number, and "range from" a first recited number to a second recited number, are used interchangeably herein and are meant to include the first recited number and the second recited number, and all fractional and integer numbers therebetween.
[0121] kit Further disclosed herein are ready-to-use kits that include the elements of the above compositions. In some embodiments, the kits include the compounds or compositions disclosed herein and one or more other components suitable for the methods of use described herein. In some embodiments, the kits include a necroptosis inhibitor or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof, and a Bax channel inhibitor compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In some embodiments, the kits include a necroptosis inhibitor or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof, and a Bax channel inhibitor compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In some embodiments, the kits include a necrostatin-1s compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof, and a Bax channel inhibitor compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In some embodiments, the kits include a necrostatin-1s compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof, and a Bax channel inhibitor compound or an analog, derivative, isomer, or pharmaceutically acceptable salt thereof. In some embodiments, the kit further comprises nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or superoxide dismutase, or any combination thereof.
[0122] In some embodiments, one or more of the components of the composition are provided as reconstituted dry powders. In such embodiments, the kit may further include a desiccant. In some embodiments, one or more of the components of the composition are provided as liquids. In some embodiments, the components of the composition are provided in kits of individual vials for preparing the composition prior to use, typically by mixing the compound or component with other components or by applying the compound or composition to other components, e.g., by supplementing the composition to a cell growth medium. In some embodiments, the kit may further include one or more of a cryoprotectant, a carrier, or an excipient. In some embodiments, the kit may further include a combination of two or more of these additional components.
[0123] In some embodiments, the kit further comprises all the brackets and containers necessary for mixing and preparing the composition for administration. In some embodiments, the components of the composition in the kit are premixed. In some embodiments, the composition of the kit is sterile. In some embodiments, the kit further comprises packaging materials. In some particular embodiments, the packaging materials are airtight. In these embodiments, the packaging materials may be optionally filled with an inert gas, such as, for example, nitrogen, argon, and the like. In some embodiments, the packaging materials comprise, for example, metal foil containers, such as sealed aluminum pouches. Such packaging materials are well known to those of skill in the art. In additional embodiments, the kit further comprises instructions that explain how to combine the components or compounds of the disclosed compositions, and, optionally, how to combine the disclosed compositions with other components (e.g., cryoprotectants, carriers, or excipients) to form a composition for administration.
[0124] method In some embodiments, the compositions disclosed herein act to prevent the progression of necrotic pathways during freeze-thaw cycles and repair physical, chemical and thermodynamic damage that occurs during cell manipulation in vitro and release from tissues. In some embodiments, the compositions disclosed herein act to inhibit necrosis of cells, tissues, or organs undergoing cryopreservation. In some embodiments, the compositions disclosed herein act to inhibit or reduce the occurrence of cellular plasticity, necroptosis, or necrosis in cells, tissues, or organs. In some embodiments, the compositions disclosed herein are useful for treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity, necroptosis, or necrosis associated with aging or disease in a subject. In some embodiments, the compositions disclosed herein may be used in methods of cryopreservation of multiple cells. In some embodiments, the compositions disclosed herein may be used in methods of treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity, or necroptosis or necrosis in multiple cells.
[0125] The compositions for use in the methods disclosed herein are described above.In some embodiments, any of the compositions described herein can be used in the methods of use described herein.In some embodiments, the combination and concentration of components contained in the composition for use in the methods of use described herein are described in detail above.
[0126] In one embodiment, provided herein is a method of cryopreservation, the method comprising: (a) contacting a plurality of cells with a composition disclosed herein; and (b) cooling the composition comprising the plurality of cells of step (a).
[0127] In one embodiment, provided herein is a method of cryopreservation, comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor and a Bax channel inhibitor; and (b) cooling the composition comprising the plurality of cells of step (a). Non-limiting examples of necroptosis inhibitors and Bax channel inhibitors are disclosed in detail above. In another embodiment, provided herein is a method of cryopreservation, comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor comprising a necrostatin-1s compound, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof, and a Bax channel inhibitor comprising 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof; and (b) cooling the composition comprising the plurality of cells.
[0128] In another embodiment, provided herein is a method of cryopreservation, the method comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, and a Bax channel inhibitor, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, and further comprising nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase, zinc superoxide dismutase, or any combination thereof; and (b) cooling the composition comprising the plurality of cells. In another embodiment, provided herein is a method of cryopreservation, the method comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor, further comprising nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese-superoxide dismutase, zinc-superoxide dismutase, or any combination thereof; and (b) cooling the composition comprising the plurality of cells, wherein the necroptosis inhibitor compound comprises 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof, and the Bax channel inhibitor compound comprises 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof.
[0129] In another embodiment, provided herein is a method of cryopreservation, the method comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound, a Bax channel inhibitor compound, and further comprising nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase, zinc superoxide dismutase, or any combination thereof; and (b) cooling the composition comprising the plurality of cells, wherein the necroptosis inhibitor compound is a Bax channel inhibitor compound. The compound is selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, 3-p-methoxyphenyl-5,6-tetramethyl-thieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide compound or a derivative, isomer, or pharma-ceutically acceptable salt thereof, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl) Thiazolidin-4-one or a derivative, isomer, or pharma- ceutically acceptable salt thereof, 5-(indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin or a derivative, isomer, or pharma- ceutically acceptable salt thereof, methylthio-hydantoin-tryptophan compound or a derivative, isomer, or pharma- ceutically acceptable salt thereof, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl) -2-hydroxyethanone or a derivative, isomer, or pharma- ceutically acceptable salt thereof, (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide or a derivative, isomer, or pharma-ceutically acceptable salt thereof, (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide or a derivative, isomer, or pharma-ceutically acceptable salt thereof, 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, or 2,2-dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one, or a derivative, isomer, or a pharma- ceutically acceptable salt thereof, and the Bax channel inhibitor comprises 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analog, derivative, isomer, or a pharma- ceutically acceptable salt thereof.
[0130] In another embodiment, provided herein is a method of cryopreservation, the method comprising: (a) administering a plurality of cells to a subject in need of cryopreservation in a culture medium comprising: (a) administering to the subject a plurality of cells a cryopreservation solution comprising between about 0.2 nM and 2 μM of 5-((7-chloro-1H-indol)-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof; between about 0.5 nM and 50 μM of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof; and (b) contacting the plurality of cells with a composition comprising a dimer, derivative, isomer, or pharma- ceutically acceptable salt thereof, about 5 nM to 500 μM nicotinamide adenine dinucleotide (NAD), about 10 nM to 1 mM adenosine triphosphate (ATP), about 1 nM to 1 mM cyclosporine A, and 0.001 KU to 100 KU manganese superoxide dismutase, zinc superoxide dismutase, or any combination thereof; and (b) cooling the composition comprising the plurality of cells. In another embodiment, provided herein is a method of cryopreservation, the method comprising: (a) contacting a plurality of cells with a composition comprising about 20 nM of 5-((7-chloro-1H-indol-3yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, about 5 nM of 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride compound, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, about 50 μM of nicotinamide adenine dinucleotide (NAD), about 10 nM of adenosine triphosphate (ATP), about 10 nM of cyclosporine A, about 0.1 KU of manganese-superoxide dismutase, zinc-superoxide dismutase, or any combination thereof; and (b) cooling the composition comprising the plurality of cells. In another embodiment, provided herein is a method of cryopreservation, the method comprising: (a) contacting a plurality of cells with any of the compositions disclosed herein; and (b) cooling the composition comprising the plurality of cells.
[0131] In another embodiment, provided herein is a method of treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in a plurality of cells, comprising contacting the plurality of cells with a composition disclosed herein.In another embodiment, provided herein is a method of treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in a plurality of cells, comprising contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor compound. In another embodiment, provided herein is a method of treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity, necroptosis, or necrosis in a plurality of cells, the method comprising contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor, wherein the necroptosis inhibitor compound comprises 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof, and the Bax channel inhibitor comprises 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof.
[0132] In another embodiment, provided herein is a method of treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity, necroptosis, or necrosis in a plurality of cells, the method comprising contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor, further comprising nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese superoxide dismutase, zinc superoxide dismutase, or any combination thereof, wherein the necroptosis inhibitor compound comprises 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof, and the Bax channel inhibitor comprises 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analogue, derivative, isomer, or pharmaceutically acceptable salt thereof.
[0133] In another embodiment, provided herein is a method of treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in a plurality of cells, the method comprising contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor, and further comprising nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, manganese-superoxide dismutase, zinc-superoxide dismutase, or any combination thereof. and the necroptosis inhibitor compound is selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, 3-p-methoxyphenyl-5,6-tetramethylenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethyl cyanide compound, (Z)-5-((3-(4-fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one, 5-(indol-3-ylmethyl) -(2-Thio-3-methyl)hydantoin, methyl-thiohydantoin-tryptophan compound, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone, (S)-N-(1-[2-chloro-6-fluorophenyl]ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide, (E)-N-(4-(N-(3-methoxypyrazin-2-yl) and the Bax channel inhibitor comprises 3,4-dihydro-5-(trifluoromethyl)phenyl)-3-(2-fluoro-5-(sulfamoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylamide, 1-(4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea, or 2,2-dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one, or a derivative, isomer, or pharma- ceutically acceptable salt of any one of said necroptosis inhibitor compounds.6-Dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, or an analogue, derivative, isomer, or pharma- ceutically acceptable salt thereof.
[0134] In another embodiment, provided herein is a method for treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in a plurality of cells, the method comprising treating the plurality of cells with about 0.2 nM to 2 μM of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analog, derivative, isomer, or pharma- ceutical acceptable salt thereof, about 0.5 nM to 50 μM of 3,6-dibromo-a-(1-piperazinylmethyl) The method includes contacting the subject with a composition comprising the compound -9H-carbazole-9-ethanol dihydrochloride, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, about 5 nM to 500 μM nicotinamide adenine dinucleotide (NAD), about 10 nM to 1 mM adenosine triphosphate (ATP), about 1 nM to 1 mM cyclosporine A, and 0.001 KU to 100 KU manganese-superoxide dismutase, zinc-superoxide dismutase, or any combination thereof. In another embodiment, provided herein is a method for treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in a plurality of cells, the method comprising treating the plurality of cells with about 20 nM of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, or an analog, derivative, isomer, or pharma- ceutical acceptable salt thereof, about 5 nM of 3,6-dibromo-a-(1-piperazinyl)methyl)-2,4-imidazolidinedione compound, or an analog, derivative, isomer, or pharma- ceutical acceptable salt thereof, or ... The method comprises contacting a plurality of cells with a composition comprising the compound 9H-carbazole-9-ethanol dihydrochloride, or an analog, derivative, isomer, or pharma- ceutically acceptable salt thereof, about 50 μM nicotinamide adenine dinucleotide (NAD), about 10 nM adenosine triphosphate (ATP), about 10 nM cyclosporine A, and about 0.1 KU manganese-superoxide dismutase, zinc-superoxide dismutase, or any combination thereof. In another embodiment, provided herein is a method for treating, preventing, inhibiting, or reducing the occurrence of cell plasticity, necroptosis, or necrosis in a plurality of cells, the method comprising contacting the plurality of cells with a composition disclosed herein.
[0135] In some embodiments, necroptosis or necrosis is associated with aging or disease. One skilled in the art will understand that the term "disease" can encompass a particular abnormal condition, disorder of structure or function that affects part or all of an organism and involves cellular plasticity, necroptosis, or necrosis. In one embodiment, the disease is myocardial infarction. In another embodiment, the disease is diabetes secondary to beta cell necroptosis. In another embodiment, the disease is cholestatic liver disease. In another embodiment, the disease is stroke. In another embodiment, the disease is organ ischemia. In another embodiment, the disease is ischemia-reperfusion injury. In another embodiment, the disease is liver disease. In another embodiment, the disease is necrosis due to cancer chemotherapy or radiation therapy. In another embodiment, the disease is traumatic brain injury. In another embodiment, the disease is necrotizing pancreatitis. In another embodiment, the disease is pathogen-induced necroptosis. In another embodiment, the disease is inflammation. In another embodiment, the disease is a neurodegenerative disease. In some embodiments, the disease comprises myocardial infarction, diabetes secondary to beta cell necroptosis, cholestatic liver disease, stroke, organ ischemia, ischemia-reperfusion injury, liver disease, necrosis due to cancer chemotherapy or radiation therapy, traumatic brain injury, necrotizing pancreatitis, pathogen-induced necroptosis, inflammation, neurodegenerative diseases.
[0136] In some embodiments, the methods disclosed herein for preventing, inhibiting, or reducing the occurrence of cellular plasticity or necrotic or necrotic death in a plurality of cells are used during the isolation, manipulation, cryoculture, or cryopreservation and freeze-thaw cycles of the plurality of cells. In some embodiments, the methods for preventing, inhibiting, or reducing the occurrence of cellular plasticity or necrotic or necrotic death include in vitro, ex vivo, or in vivo use.
[0137] One of skill in the art will understand that the term "plurality of cells" can encompass any mammalian cell or group of cells, either grown in vivo or in vitro culture, or maintained in ex vivo culture. The group of cells contemplated for the methods of use disclosed herein includes any multicellular sample. In some embodiments, the multicellular sample includes a single cell type or multiple cell types, tissues, organs, parts of organs, specific segments of whole organisms, whether within an organism or removed or extracted from an organism. In another embodiment, the plurality of cells comprises a whole organism.
[0138] In some embodiments, the compositions disclosed herein include primary cells, including stem cells, adult cells, transdifferentiated cells, dedifferentiated cells, differentiated cells, and are suitable for use with any cell type, whether cultured in vitro, in vivo, or ex vivo. In some embodiments, cell types compatible with the disclosed methods include germ cells (oocytes and spermatocytes), stem cells, acinar cells, adipocytes, alveolar cells, ameloblasts, annulus cells, arachnoid cells, astrocytes, blastoderm, calvarial cells, cancerous cells (adenocarcinoma, fibrosarcoma, glioblastoma, hepatoma, melanoma, myeloid leukemia, neuroblastoma, osteosarcoma, sarcoma), cardiomyocytes, chondrocytes, chordoma cells, chromaffin cells, cumulus cells, endothelial cells, endothelial-like cells, sheath cells, and the like. cell), epithelial cell, fibroblast, fibroblast-like cell, germ cell, hepatocyte, hybridoma, insulin-producing cell, interstitial cell, pancreatic islet, keratinocyte, lymphocyte, macrophage, mast cell, melanocyte, meniscus cell, mesangial cell, mesenchymal progenitor cell, monocyte, mononuclear cell, myeloblast, myoblast, myofibroblast, neuron, nucleus cell, odontoblast, oocyte, osteoblast, osteoblast-like cell, osteoclast, osteoclast precursor cell, oval cell, papilla cell, parenchymal cell, pericyte, periodontal ligament cell, periosteal cell, platelet, lung cell, preadipocyte, preadipocyte, kidney cell, salicyspheric cell, Schwann cell, secretory cell, smooth muscle cell, sperm cell, astrocyte, stem cell, stem cell-like cell, statoli cellCells, stromal cells, synovial cells, synoviocytes, T cells, tendon cells, T lymphoblasts, trophoblasts, urothelial cells, vitreous cells, and the like, wherein the cells are derived from any of the following tissues, for example, but not limited to, adipose tissue, adrenal gland, amniotic fluid, amniotic sac, aorta, arteries (carotid, coronary, lung), bile duct, bladder, blood, bone, bone marrow, brain (including cerebral cortex), breast, bronchus, cartilage, cervix, chorionic villi, colon, conjunctiva, connective tissue, cornea, dental pulp, duodenum, dura mater, ear, endometriotic cyst, endometrium, esophagus, eye, foreskin, gallbladder, ganglion, gums, head / neck, heart, heart valve, hippocampus, ilium, intervertebral disc, joint, jugular vein, kidney, knee, lacrimal gland, ligament, liver, lung, lymph node, mammary gland, mandible, meninges, mesoderm, , microvasculature, mucosa, muscle-derived (MD), myeloid leukemia, myeloma, nose, nasopharynx, nerve, nucleus pulposus, oral mucosa, ovary, pancreas, parotid gland, penis, placenta, prostate, kidney, respiratory tract, retina, salivary gland, saphenous vein, sciatic nerve, skeletal muscle, skin, small intestine, sphincter, spine, spleen, stomach, synovium, teeth, tendons, testes, thyroid, tonsils, trachea, umbilical artery, umbilical cord, umbilical cord blood, umbilical vein, umbilical cord (Wharton's jelly), urinary tract, uterus, vasculature, ventricle, vocal cord and cells, or any combination thereof, the tissue being derived from, for example, but not limited to, any of the following species: baboon, buffalo, cat, chicken, cow, dog, goat, guinea pig, hamster, horse, human, monkey, mouse, pig, quail, rabbit, etc.
[0139] In some embodiments, the plurality of cells comprises tissue culture cells, primary cells, germ cells, such as egg cells and / or sperm, tissues, organs or portions thereof, or any combination thereof. In some embodiments, the tissue culture cells or primary cells comprise stem cells, adult cells, transdifferentiated cells, dedifferentiated cells, or differentiated cells, or any combination thereof. In some embodiments, the plurality of cells comprises human cells or animal cells.
[0140] Those skilled in the art will understand that the term "in vivo" encompasses the methods of use described herein that are performed on a living organism in its natural state. For example, in one embodiment, contacting a plurality of cells in vivo comprises perfusion of an animal or a portion thereof. In another embodiment, contacting a plurality of cells in vivo comprises perfusion of an organ or a portion thereof in an intact animal.
[0141] Those skilled in the art will understand that the term "ex vivo" encompasses the methods of use described herein that are carried out outside of an organism. For example, in one embodiment, ex vivo contacting of a plurality of cells may include exposing the cells, if they are primary cells, to an artificial environment (sterile conditions) outside the organism from which the cells originate, with minimal changes in natural conditions. For example, in one embodiment, ex vivo contacting of a plurality of cells includes perfusion of an organ or a portion thereof removed from a subject. In another embodiment, ex vivo contacting of a plurality of cells includes perfusion of a tissue or a portion thereof removed from a subject. In some embodiments, the subject includes an animal or a human.
[0142] Those skilled in the art will understand that the term "in vitro" encompasses the methods of use described herein that occur in an artificial environment. For example, in one embodiment, contacting a plurality of cells in vitro includes mixing a composition disclosed herein with a plurality of cells not in an organism (e.g., an animal), in a test tube or reaction vessel, in cell culture medium, in a petri dish, or in another artificial environment known in the art.
[0143] In one embodiment, contacting the plurality of cells with a composition disclosed herein occurs in vivo, ex vivo, or in vitro.
[0144] The methods disclosed herein provide for contacting a plurality of cells with the compositions disclosed herein, thereby preserving and protecting the cells before damage occurs during the process of derivation and isolation or downstream manipulation, including cryopreservation. The contacting step can be performed in vivo, for example, in some embodiments prior to removal of a plurality of cells from an organism. In another embodiment, the in vivo contacting step is systemic, delivering the composition of the present invention to all cells and organs of the organism. In another embodiment, the in vivo contacting step is localized, delivering the composition of the present invention locally to the site of cell procurement. Suitable delivery methods are readily apparent to those skilled in the art and include injection, intravenous perfusion, intracoronary myocardial perfusion, intraarterial organ perfusion by catheter, coronary sinus perfusion, intracardiac perfusion, or any method known in the art.
[0145] The compositions can also be applied to gross tissues, for example, via the process of non-thermally reversible electroporation, or to perfusion bioreactor systems using three-dimensional culture, and to living organs for transplantation.These compounds have excellent cell penetration capabilities, making them ideal for the protection of biological tissues and materials across a wide range of applications and species.
[0146] In some embodiments, the contacting step is performed in vitro, for example on cells isolated from tissue culture or an organism. In some embodiments, the in vitro contacting step comprises immersing a plurality of cells in a composition disclosed herein immediately after procurement. In another embodiment, the in vitro contacting step comprises immersing a plurality of cells in a composition shortly after procurement. In another embodiment, the in vitro contacting step comprises replacing the growth medium of the in vitro culture with a composition disclosed herein. In another embodiment, the in vitro contacting step comprises supplementing the growth medium of the in vitro culture with a composition disclosed herein. In another embodiment, the in vitro contacting step comprises rapid infusion with a composition disclosed herein by non-thermally reversible electroporation. In another embodiment, the in vitro contacting step comprises incubating a plurality of cells immersed in a composition disclosed herein in a perfusion bioreactor. In another embodiment, the in vitro contacting step comprises incubating a plurality of cells immersed in a composition disclosed herein in a 3D culture. In another embodiment, contacting a plurality of cells with a composition disclosed herein comprises contacting the plurality of cells in vivo or ex vivo, wherein the contacting comprises perfusion of an animal or a portion thereof, an organ or a portion thereof, or a tissue.
[0147] In some embodiments, the compositions disclosed herein are introduced via transcardial perfusion into animals or humans, thereby entering all organs and cells within seconds.Tissues and organs isolated from these sources are then kept in the composition throughout the subsequent steps until plating, transfer, or freezing.This includes cells that dissociate during this process and are kept in solution until subsequent plating or freezing.In some embodiments, organs from subjects are processed in certain organ transplant procedures where the necessary solutions are reformulated to contain the composition, so that necrosis and necroptosis are avoided and cells within the tissue are protected.
[0148] In some embodiments, the perfusion comprises cardiac perfusion. In some embodiments, contacting the plurality of cells in vitro comprises soaking the plurality of cells in a composition disclosed herein, or supplementing the growth medium of the plurality of cells with a composition disclosed herein, or perfusing the plurality of cells with a composition described herein by non-thermal reversible electroporation, or perfusing the plurality of cells with a composition disclosed herein in a bioreactor.
[0149] In some embodiments, the bioreactor is used to grow and propagate a plurality of cells. In some embodiments, the bioreactor can be used for culturing cells, where the conditions are suitable for high cell concentration. In another embodiment, the bioreactor provides a closed system for cell growth. In another embodiment, multiple bioreactors are used for sequential cell growth. In another embodiment, the bioreactor used in the methods disclosed herein is a single-use bioreactor. In another embodiment, the bioreactor used is a multi-use bioreactor. In yet another embodiment, the bioreactor comprises a control unit for monitoring and controlling the parameters of the process.
[0150] In some embodiments, the compositions disclosed herein are rapidly injected into tissues derived from animals or humans, for example, via non-thermal reversible electroporation or via a perfusion bioreactor system using three-dimensional culture.Other tissue injection mechanisms can be used as well.In other embodiments, the tissue can be derived from an in vitro source, where the composition can be injected in vitro upon exchange of growth medium or other supporting solution.
[0151] In some embodiments, tissue from a human subject can be harvested and perfused with the compositions disclosed herein at the time of procurement. This can be accomplished by pre-treating with the composition locally at the procurement site or in vitro immediately after tissue isolation. In some embodiments, the tissue can be procured and placed in a container pre-filled with the composition solution at the same time.
[0152] In some embodiments, tissues from animals or humans are placed in the compositions disclosed herein and processed to liberate cells for cryopreservation or for use in in vitro cell culture, where the tissue and cells are continuously exposed to the compositions, with changes in solution accompanied by appropriate additions of the compositions, allowing for preservation and protection from necrosis and necroptosis.
[0153] Introduction of the compositions disclosed herein via transcardial perfusion of a living animal (e.g., the animal includes a pregnant female adult animal) results in rapid preservation of all organs and cells, including penetration into embryonic tissues across the body axis, including privileged organs such as the brain. Also, simple in vitro introduction into tissues or any of a number of cells described herein allows for rapid penetration and activation. This is a surprising new way to preserve the metabolic state of cells before they begin to die in tissue or cell procurement techniques, a kind of "metabolic arrest."
[0154] In some embodiments of the methods disclosed herein, the plurality of cells can be subjected to a physical, chemical or thermodynamic manipulation after the step of contacting the plurality of cells with the composition disclosed herein. In some embodiments of the methods disclosed herein, the plurality of cells can be subjected to a physical, chemical or thermodynamic manipulation simultaneously with the step of contacting the plurality of cells with the composition disclosed herein. In some embodiments of the methods disclosed herein, the plurality of cells can be subjected to a physical, chemical or thermodynamic manipulation before the step of contacting the plurality of cells with the composition disclosed herein.
[0155] In some embodiments, the additional processing step in the methods disclosed herein comprises liberating individual cells from a plurality of cells derived from an animal or human, its organs, or its tissues. In another embodiment, the additional processing comprises proteolytic digestion of extracellular proteins. In another embodiment, the additional processing comprises cell sorting. In another embodiment, the additional processing comprises treating the cells with various chemicals and signaling molecules, for example to induce or inhibit cell proliferation or differentiation. In another embodiment, the additional processing comprises centrifugation and resuspension of the cells, for example to concentrate the cells.
[0156] In some embodiments, all intermediate operations are performed while the cells are submerged in a composition disclosed herein, hi some embodiments, all intermediate operations are performed while the cells are submerged in a growth medium supplemented with a composition disclosed herein.
[0157] In some embodiments, the methods disclosed herein include a thermodynamic manipulation that includes heating or cooling a plurality of cells. In another embodiment, the cooling includes cryopreservation or freeze-thaw cycles, or a combination thereof. In another embodiment, the cooling includes multiple freeze-thaw cycles.
[0158] In some embodiments, the step of cooling the composition described herein comprising a plurality of cells comprises lowering the overall temperature of the plurality of cells immersed or perfused in the composition disclosed herein. In one embodiment, the temperature is lowered below freezing, e.g., for long-term storage. In another embodiment, the temperature is lowered to near freezing for short or medium term use, e.g., prior to further manipulation of the cells, such as transplantation, re-transplantation, or separation of a specific type of cell from the plurality of cells.
[0159] In some embodiments, a plurality of cells is immersed or perfused with a composition disclosed herein, and the composition comprising the cells is rapidly cooled. In another embodiment, a plurality of cells is immersed or perfused with a composition disclosed herein and gradually cooled. In another embodiment, rapid cooling is performed to prevent denaturation of proteins in the cells undergoing cooling. In another embodiment, slow cooling is performed to induce a state of metabolic arrest in the cells undergoing cooling.
[0160] In some embodiments of the methods disclosed herein, the composition is pre-cooled prior to contacting the plurality of cells with the composition. In some embodiments of the methods disclosed herein, the composition is pre-heated to match the culture temperature prior to contacting the plurality of cells with the composition. In some embodiments of the methods disclosed herein, the composition is cooled simultaneously with contacting the plurality of cells with the composition.
[0161] In one embodiment, provided herein is a method of inducing a state of metabolic arrest in a plurality of cells, the method comprising: (a) contacting the plurality of cells with a composition disclosed herein. In another embodiment, a method for inducing a state of metabolic arrest in a plurality of cells comprises: (a) contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor; and (b) optionally cooling the plurality of cells. In some embodiments, the state of metabolic arrest comprises a reversible cessation of oxygen metabolism. In some embodiments, the state of metabolic arrest is induced during or after cryopreservation and / or freeze-thaw cycles thereof as described herein. In some embodiments, the state of metabolic arrest is induced during or after a method of treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity or necroptosis or necrosis in a plurality of cells as described herein.
[0162] Those skilled in the art will understand that the term "metabolic arrest" may encompass the slowing and / or cessation of metabolic biochemical pathways, including the cessation of oxygen metabolism. In some embodiments, the methods disclosed herein induce a state of metabolic arrest, thereby protecting viability and preserving cellular identity. For example, in another embodiment disclosed herein, the methods disclosed herein induce metabolic arrest in stem cells and adult cells that are to be reprogrammed, dedifferentiated, or transdifferentiated into new cell types, and the identity of the reprogrammed, dedifferentiated, or transdifferentiated cells is maintained. In some embodiments, the methods disclosed herein of inducing metabolic arrest preserve the metabolic state of the cells, thereby preventing cell death due to stress caused by tissue or cell procurement procedures. In some embodiments, the methods disclosed herein induce metabolic arrest and enhance cell viability. In some embodiments, the methods disclosed herein using the compositions disclosed herein prevent, inhibit, or reduce changes in the differentiation state of a plurality of cells contacted with the compositions disclosed herein, and the identity of the cells is stable compared to a non-contacted cell population or a population contacted with a composition known in the art. In another embodiment, the methods disclosed herein result in a plurality of cells that retain their cellular identity. In another embodiment, the identity of a cell is retained during cooling of the cell. In another embodiment, the identity of a cell is retained during freezing of the cell. In another embodiment, the identity of a cell is retained during and after freeze-thaw cycles performed as part of cryopreservation of the cell. In another embodiment, the identity of a cell is retained during physical manipulation of the cell. In another embodiment, the identity of a cell is retained during storage of the cell.
[0163] In some embodiments, the methods disclosed herein prevent, inhibit, or reduce necrosis or necroptotic death of the plurality of cells during cryopreservation or freeze-thaw cycles thereof, as compared to a plurality of control cells not contacted with a composition disclosed herein. In some embodiments, the methods disclosed herein prevent, inhibit, or reduce necrosis or necroptotic death of the plurality of cells during a method comprising freeze-thaw cycles, as compared to a plurality of control cells not contacted with a composition disclosed herein.
[0164] In some embodiments, the methods disclosed herein protect a plurality of cells from physical damage during the cryopreservation step or freeze-thaw cycle. In another embodiment, the physical damage from cryopreservation of the freeze-thaw cycle includes cell shrinkage and dehydration due to ice formation upon freezing. Rapid loss of intracellular water can occur as a result of initial extracellular ice crystal formation followed by increased osmotic forces. Accompanying this water loss is a concomitant loss of significant levels of cellular metabolites. For example, in another embodiment, ATP and NAD can be lost during the cryopreservation process or freeze-thaw cycle. In another embodiment, cells are temporarily physically "poked" open at the plasma membrane, temporarily exposing open pores through which metabolites can be lost.
[0165] In some embodiments, the methods disclosed herein protect a plurality of cells by inhibiting or reducing excessive calcium release in the cells, by inhibiting or reducing excessive ATP release from the cells, by inhibiting or reducing excessive NAD release from the cells, or by inhibiting activation of pathways that lead to necrosis and necroptosis, or any combination thereof. In some embodiments, the methods disclosed herein protect a plurality of cells, e.g., an organ or portion thereof, or tissue, by inhibiting or reducing lack of oxygenation, free radical generation, or ischemia, or any combination thereof. In another embodiment, the methods disclosed herein protect a plurality of cells, e.g., an organ or portion thereof, or tissue, by inhibiting or reducing intracellular Ca 2+The present invention provides protection to multiple cells by inhibiting or reducing the increase in the concentration of ATP, the activation of PARP in cells leading to a decrease in NAD and ATP levels, or an increase in reactive oxygen species, or any combination thereof.
[0166] Those skilled in the art will understand that the term "physical damage" can include any disruption of physiological cell function or cell death. Non-limiting examples of disruption of physiological cell function include oxidative stress (e.g., lipid peroxidation, DNA and RNA oxidation, protein oxidation), non-specific glycation, protein misfolding, DNA mutation, loss of cell structure integrity, metabolic stress, thermodynamic stress, temperature fluctuation shock, ionizing and non-ionizing radiation damage and chemical stress (e.g., exposure to acid or basic substances). Thus, the phrase "protection from physical damage" in some embodiments encompasses either prevention or reduction of cell death or prevention or reduction of the deterioration of cell function, compared to control cells that are not contacted with the compositions disclosed herein.
[0167] In some embodiments, the cryopreservation method enhances the proliferation potential of the plurality of cells compared to non-contacted plurality of cells or plurality of cells contacted with known cryopreservation solutions. In another embodiment, the duration of storage of cells is increased after cryopreservation using compositions disclosed herein. In another embodiment, the cryopreservation method enhances the proliferation potential of the plurality of cells, and the use of compositions disclosed herein provides superior post-thaw cell viability, proliferation potential and differentiation characteristics across species and cell types compared to cells cryopreserved using compositions known in the art. In another embodiment, provided herein is a method of enhancing proliferation potential in a plurality of cells during isolation, manipulation, low-temperature culture, or their cryopreservation and freeze-thaw cycles, the method comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor; and (b) optionally cooling the plurality of cells.
[0168] In some embodiments, the methods described herein preserve the health and viability of isolated cells or cells in tissues or organs, thereby enhancing the medical efficacy and usefulness of cells in transplantation, regeneration and reproductive medicine applications, such as biobanking, and cell preservation for in vitro fertilization. Thus, in another embodiment, provided herein is a method of preserving cells for in vitro fertilization, comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor; and (b) optionally cooling the plurality of cells. In another embodiment, provided herein is a method for biobanking of individualized cellular medicine samples, comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor; and (b) optionally cooling the plurality of cells. In another embodiment, provided herein is a method of preserving cells for regenerative medicine and cosmetic surgery, comprising: (a) contacting a plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor; and (b) optionally cooling the plurality of cells.
[0169] One of skill in the art will understand that the term "enhancing proliferation potential" can include a measurable increase in the mitotic cell division rate of a cell compared to a control cell that is not treated with a composition disclosed herein.
[0170] In some embodiments, the methods disclosed herein using the compositions disclosed herein improve the viability or viability potential of cells compared to non-contacted cells or cells contacted with compositions known in the art.
[0171] The main source of cellular damage during its life span is through the oxidative cellular respiration pathway and the normal processes of energy production and maintenance, which are intensified under various cellular stressors and environmental conditions, during which the ability of the cellular machinery to compensate for these changes is compromised. The stressors tax the mechanisms that protect against excessive oxidative damage to many cellular substrates, triggering a feedback loop that rapidly escalates the damage and leads to a vulnerable stage of cell viability.
[0172] One example of a condition that causes this vulnerability is the temperature fluctuation shock that occurs during the freeze-thaw process of cryopreservation. Furthermore, during the dissection of animal organs, the isolation of cells from tissues during a biopsy, or the isolation of stem cells for proliferation and differentiation in a bioreactor for cell processing purposes, all inflict damage in the process. This damage includes physical damage when removing the cells from the tissue or organ, chemical damage when introducing agents that facilitate the removal of this cell, and environmental damage when the cells are removed from their source of metabolic nutrition, such as lack of sufficient oxygen supply (ischemia) or changes in osmotic pressure.
[0173] In some embodiments, the cryopreservation methods disclosed herein using the compositions described herein prevent oxidative damage to the cells compared to non-contacted cells or cells contacted with a known cryopreservation solution, in some embodiments, the cryopreservation methods disclosed herein using the compositions described herein prevent ischemia of the cells during cryopreservation of the freeze-thaw cycle compared to non-contacted cells or cells contacted with a known cryopreservation solution.
[0174] In some embodiments, the methods disclosed herein for treating, preventing, inhibiting or reducing the occurrence of cryopreservation, or cell plasticity, or necroptosis or necrosis in a plurality of cells inhibit necrotic pathway signaling in the plurality of cells. In another embodiment, inhibition of the necrotic pathway can be at any level of the pathway.
[0175] In one embodiment, provided herein is a method of cryopreservation, which induces a state of metabolic arrest in a plurality of cells during cryopreservation and freeze-thaw cycles thereof, the method comprising: (a) contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor, and (b) cooling the plurality of cells. In one embodiment, provided herein is a method of improving viability of a plurality of cells, the method comprising: (a) contacting the plurality of cells with a composition comprising a necroptosis inhibitor compound and a Bax channel inhibitor, and (b) optionally cooling the plurality of cells. EXAMPLES
[0176] Tissue dissection and cell manipulation were studied in several cell types, in which the relative levels of reactive oxygen species (ROS) were measured as a function of Nox1 levels, the relative levels of apoptosis were measured as a function of CASP3 levels, and the relative levels of necrosis were measured as a function of staining with PI and / or Annexin V.
[0177] Example 1. Cryopreservation solution reduced the levels of reactive oxygen species (ROS), apoptosis, and necrosis resulting from tissue dissection and cell manipulation.
[0178] Tissue dissection and cell manipulation of mouse cortical neuronal tissue was studied in the presence and absence of cryopreservation solutions (Solution (Soln,soln)). (For Figure 1A-1C, Solution (Soln / soln): 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 µM adenosine triphosphate (ATP), 0.01 µM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase. ) Tissue dissection and cellular manipulation of freshly dissected tissue (Fresh) generated reactive oxygen species (ROS) (Figure 1A), whereas little ROS was observed in undissected tissue (Mock). Freshly dissected tissue (Fresh) resulted in a several-fold increase in ROS generation, whereas inclusion of a cryopreservation solution (Solution) reduced ROS levels in freshly dissected tissue (Fresh + Solution) (Figure 1A).
[0179] Figure 1B shows that apoptosis was enhanced after dissection (Fresh) compared to non-manipulated tissue (Mock), but to a lesser extent than ROS generation (Figure 1A) or necrosis (Figure 1C), which was reduced back to baseline levels by inclusion of cryopreservation solution (+Solution). Figure 1C shows that necrosis was enhanced after tissue dissection and cell manipulation (Fresh) compared to no tissue manipulation (Mock), and this effect was almost completely eliminated by inclusion of cryopreservation solution (+Solution).
[0180] Example 2. Cryopreservation solutions reduced the levels of reactive oxygen species (ROS), apoptosis, and necrosis resulting from freezing and subsequent thawing of cells.
[0181] Neuronal cell freeze / thawing was studied over time with respect to levels of ROS, apoptotic, and necrotic markers in many cell types. (For Figures 2A-2C, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 µM adenosine triphosphate (ATP), 0.01 µM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase) (CypD-cyclophilin D). Freezing / thawing of neurons resulted in ROS (detection of Nox1) compared to pre-frozen tissue (mock), and this effect was almost completely abolished by inclusion of the cryopreservation solution (+ solution) (Figure 2A). Apoptosis was slightly enhanced after freezing / thawing (Frozen) compared to pre-frozen tissue (Mock), an effect that was reduced by the inclusion of cryopreservation solution during the freezing process (+Solution) (Figure 2B). Necrosis was significantly enhanced after freezing / thawing (Frozen) compared to pre-frozen tissue (Mock), an effect that was largely eliminated by the inclusion of cryopreservation solution (+Solution) (Figure 2C).
[0182] Example 3. Motor neuron stem cells frozen in cryoprotectant solution maintained their motor neuron identity.
[0183] Freezing / thawing cycles of cells results in loss of stem cell identity, as judged by the level of CHAT1 in motor neurons. Stem cells (motor neuron progenitor cells) cultured to express CHAT1 (fresh) and then frozen in a solution containing 0.01 μM cyspA (cyclosporine A), or 20 nM Nec1, or 5 nM iMAC2 maintained CHAT1 levels compared to stem cells frozen without the presence of these compounds (frozen) that exhibited very low levels of CHAT1+ cells after freezing (Figure 3). As shown here (Figure 3), cyspA, Nec1, and IMAC2 each provided cryoprotection to stem cells upon freezing and maintained cellular properties. As judged by the level of CHAT1, the cryoprotectants in the solutions used to freeze the cells maintained their motor neuron identity.
[0184] Example 4. Cryopreservation solution maintained cell viability of frozen dissected hippocampal neurons.
[0185] In one embodiment of the cryopreservation solution, the viability of fresh versus frozen cells was analyzed by the maintenance of dissected cells (hippocampal neurons). Cell viability of neurons was measured after 7 days in vitro. No cryopreservation solution was added to the vehicle, but Necrostatin 1 (Nec1), Cyclosporine A (CspA), iMAC2 (iMAC2), or a combination of these three reagents (combination) were introduced into the cells before the freeze / thaw process. In one embodiment (combination + perfusion), the three-reagent cryopreservation solution was perfused briefly into live pregnant mice just before the pups were separated from their dams, and then hippocampal neurons were isolated from the pups at E18 (embryonic day 18). The concentrations of the various components are those used in Figure 4A. (Solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) Symbols in Figure 4A and throughout the figure: "Fresh" represents cells immediately after dissection, "Fresh + solution" represents cells immediately after dissection in composition solution, "Frozen" represents frozen / thawed cells, and "Frozen + solution" represents frozen / thawed cells in composition solution. The cryopreservation solution disclosed herein was able to increase the viability of cells immediately after dissection as well as cells frozen in an embodiment of the cryopreservation solution and then thawed (FIG. 4A). Metabolic arrest of cells (hippocampal neurons) increases the viability of the cells, and the percentage of viability provided by the various components of the cryopreservation solution is shown (FIG. 4B).
[0186] Example 5. Using a cryopreservation solution avoids the supercooling effect that can damage cells.
[0187] A comparative study was conducted on the temperature change over time during freezing in any embodiment of the cryopreservation solution disclosed herein (EVERGREEN™ media solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, 0.1 Kunitz units manganese superoxide dismutase) versus conventional media (Figure 5). There was a noticeable absence of the initial downward spike in temperature that occurred in conventional media (Figure 5 inset). Thus, these results indicated that the freezing process used herein avoids the cell-damaging supercooling effect.
[0188] Example 6. Cryopreservation solution maintained cell viability of cortical neuronal cells and adipose stem cells over time.
[0189] The viability and proliferation of cortical neurons and adipose (fat tissue) stem cells were monitored over time in cryopreservation solutions, both fresh and frozen. (For Figures 6A-6D, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.)
[0190] Viability of cortical neuronal cells was maintained when freshly dissected cells were suspended in a cryopreservation solution embodiment disclosed herein (fresh+solution) or dissected in a cryopreservation solution embodiment disclosed herein and then frozen (frozen+solution) (FIG. 6A). FIG. 6B shows the time course of neuronal viability over time (days) after plating cells exposed to these freezing and non-freezing conditions. The inclusion of cryopreservation solution was compared to the same cells exposed to 10% DMSO prior to freezing (frozen) or freshly dissected cells without cryoprotectant (fresh).
[0191] Similarly, viability of adipose (adipose tissue-derived) stem cells was maintained when freshly dissected cells were suspended in an embodiment of the cryopreservation solution disclosed herein (fresh+solution) or when dissected in an embodiment of the cryopreservation solution disclosed herein and then frozen (frozen+solution) (Figure 6C). Figure 6D shows the time course of adipose stem cell viability over time (days) after plating cells exposed to these freezing and non-freezing conditions. The inclusion of cryopreservation solution was compared to the same cells exposed to 10% DMSO prior to freezing (frozen) or freshly dissected cells without cryoprotectant (fresh).
[0192] Example 7. Cryopreservation solution reduced the number of apoptotic cells after dissection and freeze / thaw.
[0193] Apoptosis of primary liver hepatocytes after dissection and freezing / thawing was investigated with and without cryopreservation solution (for Figures 7A-7B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase). 7A shows a comparison of the effect of cryoprotectants on early apoptotic cells (primary liver hepatocytes) from fresh and frozen cells suspended in an embodiment of a cryopreservation solution disclosed herein compared to cells suspended in the absence of such solution (mock). Frozen cells not treated with cryopreservation solution (mock) were suspended in 10% DMSO prior to freezing. Caspase 3 (green) labels cells in an early apoptotic state in culture. FIG. 7B shows the number of apoptotic cells as defined by Annexin V labeling in fresh or frozen and thawed cells suspended in an embodiment of a cryopreservation solution disclosed herein or in the absence of such solution (mock). The addition of cryopreservation solution reduced the number of apoptotic cells.
[0194] Example 8. Cryopreservation solution reduced the number of necrotic cells after dissection and freeze / thaw.
[0195] Necrosis after dissection and freeze / thaw of cortical neuronal cells suspended in the presence or absence of embodiments of the cryopreservation solutions disclosed herein was investigated. (For Figures 8A-8B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.)
[0196] Figure 8A shows a comparison of the presence of necrotic cells from solutions of fresh and frozen cells suspended in an embodiment of a cryopreservation solution disclosed herein compared to cells suspended in the absence of such a solution. Anti-cyclophilin antibodies label cells in an early apoptotic state in culture. Figure 8B shows the percentage of necrotic cells following dissection performed in an embodiment of a cryopreservation solution or in the absence of such a solution. The addition of a cryopreservation solution reduced the number of necrotic cells.
[0197] Example 9. Cryopreservation solution reduced reactive oxygen species (ROS) generation after dissection and freeze / thaw compared to the traditional cryoprotectant DMSO.
[0198] The generation of reactive oxygen species (ROS) (Nox1 as a marker) in cortical neuronal tissue after dissection and freezing / thawing was investigated for the cryopreservation solution (solution) of the present invention versus a conventional cryoprotectant (DMSO). (For Figures 9A-9B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.)
[0199] Figure 9A shows Nox1 staining in fresh (dissected in saline only, not frozen) neurons, fresh neurons dissected in cryopreservation solution (fresh + solution), neurons frozen in suspension in an embodiment of the cryopreservation solution disclosed herein and then thawed (frozen + solution), or neurons similarly treated in the presence of a conventional cryoprotectant (10% DMSO, dimethylsulfoxide) (frozen). Fresh or thawed neurons were plated, post-adhesion fixed, and labeled for 4 hours. NADPH oxidase (Nox1) labels intracellular ROS. NeuN staining of cortical neurons (but not glia). 9B shows ROS generation (Nox1 intensity) in cortical neuronal tissue only immediately after dissection (fresh, blue bar), in fresh cortical neuronal tissue dissected in suspension of an embodiment of a cryopreservation solution disclosed herein (fresh+solution, red bar), in frozen cells suspended in an embodiment of a cryopreservation solution disclosed herein (frozen+solution, yellow bar) and then thawed, or in cells frozen in the presence of 10% DMSO and then thawed (green bar). Addition of the cryopreservation solution (solution) of the present invention reduced ROS generation relative to the conventional cryoprotectant DMSO.
[0200] Example 10. Cryopreservation solution preserved neuronal cell lines with much more motor neuron markers than the traditional cryoprotectant DMSO.
[0201] The preservation of motor neuron markers of neuronal lineage (MN stem cell identity) was investigated as a comparison of the cryopreservation solution of the present invention with the conventional cryoprotectant DMSO. (For Figures 10A-10B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.) Figure 10A shows photomicrographs of neurons before and after freezing in the presence or absence of the cryopreservation solution disclosed herein (10% DMSO only). FIG. 10B shows motor neuron cell identity (as measured by the presence of CHAT1 positive, S100 positive immunofluorescence signals) in cells before and after freezing with a conventional cryopreservation solution (10% DMSO) and an embodiment of a cryopreservation solution disclosed herein ("post-freeze composition"). MN stem cell identity was preserved after using the composition solution than after using the conventional cryopreservation solution, DMSO. Neuronal lineage of motor neuron markers was significantly preserved compared to the composition solution than when using a conventional cryoprotectant (10% DMSO).
[0202] Example 11. Cryopreservation solution preserved hepatocyte activity after freeze / thaw.
[0203] The effect of cryopreservation solutions on hepatocyte activity after freezing / thawing was investigated in comparison to fresh samples. (For Figures 11A-11B, solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.)
[0204] FIG. 11A shows a comparison of fresh and frozen liver cells (blue staining) incubated in the presence or absence (fresh, not frozen) of the cryopreservation solution disclosed herein, and not stimulated (-galactosamine) or stimulated with galactosamine for a short period before fixation, and stained with antibody-bound uridine (red staining) as a general measure of galactosamine-induced transcription. FIG. 11B shows a comparison of hepatocyte transcriptional activity in fresh and frozen cells suspended in an embodiment of the cryopreservation solution disclosed herein, and hepatocyte activity is similar after freezing / thawing when cells are maintained in the presence of the cryopreservation solution disclosed herein. The bar is a measure of antibody-bound uridine staining (arbitrary units). Primary mouse liver cells (hepatocytes) show similar physiological properties after freezing / thawing in the presence of the composition solution compared to freshly dissected tissue.
[0205] Example 12. Comparison of several necrostatin analogues for cryoprotective effect.
[0206] Several analogs of necrostatin were investigated and found to perform similarly in cryoprotective effects after freezing / thawing. Figure 12 shows the effect of cryopreservation solutions containing various necrostatins. The presence of necrostatins (Nec1 (red bars), Nec2 (yellow bars), Nec3 (green bars)) significantly enhanced the viability of primary mouse cortical neuronal cells compared to control cells (vehicle, blue bars) cryopreserved in conventional cryoprotectant (10% DMSO). The concentration of various necrostatins was 20 nM, while other components of the "solution" remained the same, i.e., 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 µM adenosine triphosphate (ATP), 0.01 µM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.
[0207] Example 13. Cryopreservation solution inhibited necroptosis markers in hepatocytes.
[0208] The expression of necroptosis markers in primary mouse hepatocytes (hepatocytes) was investigated before and after freezing in either the cryopreservation solution of the present invention or the conventional cryopreservation solution DMSO. (The cryopreservation solution used here was 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase.)
[0209] Figure 13A shows images of primary mouse hepatocytes (hepatocytes) before and after freezing in a conventional cryopreservation solution (10% DMSO) and in an embodiment of a cryopreservation solution disclosed herein ("Composition Freezing"). The cells here are stained with an antibody that recognizes HMBG1 (green) as a marker of necroptosis. Figure 13B shows that necroptosis markers were significantly inhibited in cell suspensions of an embodiment of a cryopreservation solution disclosed herein compared to 10% DMSO ("DMSO Freezing").
[0210] Example 14. TNF-α production in necroptosis-induced THP-1 cells was significantly reduced using cryopreservation solutions.
[0211] NF-α production in necroptosis-induced THP-1 cells was investigated with respect to a cryopreservation solution (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase, EVERLAST™. Briefly, necrotic cell lysates were first generated and used in the assay of THP-1 cell cytokine production. Necrotic cell lysates were generated by taking THP-1 cells, culturing them in 60 mm dishes in complete medium (RPMI 1640 supplemented with 2 mM glutamine, 10% fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin) at 1 million cells per ml, and stimulating with 0.5 μg / ml LPS. After approximately 12 hours, the cells were harvested, washed briefly (twice with 10x volume) with PBS, and resuspended in complete medium at 1 million cells / mL. These cells were then used to induce necrosis by repeatedly freezing (5-6 cycles) in liquid nitrogen and thawing to 37°C. Lysates were made by centrifugation at 15K RPM (24Kxg) for 20 minutes at 4°C, and added to freshly cultured THP-1 cells at a 50% volume / volume ratio in fresh medium. The medium was also supplemented with 0.5 μg / mL LPS for maximum cytokine production. TNF-α and IL-6 protein concentrations were measured in culture supernatants using ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. Each sample was assayed in duplicate, with known cytokine protein measurements as reference standards. Data are the mean + standard error of the mean (SEM) of three independent experiments. p values were calculated using Student's T-test.
[0212] Results of TNF-α ELISA assay after culturing THP-1 cells and inducing them to produce proinflammatory cytokines with necrotic cell lysate combined with lipopolysaccharide (LPS). Figure 14 shows TNF-α levels (pg / mL) after mock stimulation (1-3), after LPS stimulation only (4-6), after LPS stimulation in the presence of 10% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol (7-9), after LPS stimulation in the presence of 100% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol (10-12). (*) Significant differences (p<0.01) between mock (1-3) and LPS alone (4-6), and between LPS alone (4-6) and LPS + 10% EVERGREEN™ vehicle solution (7-9). (**) Significant difference (p<0.001) between LPS alone (4-6) and LPS + 100% EVERGREEN™ vehicle solution (10-12).
[0213] TNF-α production in necroptosis-induced THP-1 cells was significantly reduced by the EVERGREEN™ cryopreservation solution of the present invention.
[0214] Example 15. IL-6 production in necroptosis-induced THP-1 cells was significantly reduced using cryopreservation solutions.
[0215] IL-6 production in necroptosis-induced THP-1 cells was investigated with respect to the effect of a cryopreservation solution of the present invention (EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; EVERLAST™.
[0216] Briefly, necrotic cell lysates were first generated and used in assays of THP-1 cell cytokine production. Necrotic cell lysates were generated by taking THP-1 cells, culturing them in 60 mm dishes in complete medium (RPMI 1640 supplemented with 2 mM glutamine, 10% fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin) at 1 million cells per ml, and stimulating them with 0.5 μg / ml LPS. After approximately 12 hours, the cells were harvested, washed briefly (twice with 10x volume) with PBS, and resuspended in complete medium at 1 million cells / mL. These cells were then used to induce necrosis by repeatedly freezing (5-6 cycles) in liquid nitrogen and thawing to 37°C. Lysates were made by centrifugation at 15K RPM (24Kxg) for 20 minutes at 4°C and added to freshly cultured THP-1 cells at 50% volume / volume ratio in fresh medium. This medium was also supplemented with 0.5 μg / mL LPS for maximum cytokine production. TNF-α and IL-6 protein concentrations were measured in the culture supernatants using ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. Each sample was assayed in duplicate, with known cytokine protein measurements as reference standards. Data are the mean + standard error of the mean (SEM) of three independent experiments. p values were calculated using Student's T-test.
[0217] Results of ELISA assay of IL-6 after THP-1 cells were cultured and induced to produce proinflammatory cytokines with necrotic cell lysate in combination with lipopolysaccharide (LPS). Figure 15 shows the IL-6 levels (pg / mL) measured after (1-3) mock stimulation, (4-6) LPS stimulation only, (7-9) LPS stimulation in the presence of 10% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol, and (10-12) LPS stimulation in the presence of 100% activity level of EVERGREEN™ vehicle solution used in the cryopreservation protocol. (*) Significant difference (p<0.01) between mock (1-3) and LPS alone (4-6), and between LPS alone (4-6) and LPS + 10% EVERGREEN™ vehicle solution (7-9). (**) Significant difference (p<0.001) between LPS alone (4-6) and LPS + 100% EVERGREEN™ vehicle solution (10-12).
[0218] IL-6 production in necroptosis-induced THP-1 cells was significantly reduced by the EVERGREEN™ cryopreservation solution of the present invention.
[0219] Example 16. Consistency of IL-6 cytokine release measurements using cryopreservation solutions.
[0220] The cryopreservation solution of the present invention, EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; EVERLAST™, provided significant consistency in cytokine release measurements ( FIG. 16 ). Variability was calculated by averaging the percent error for each (triplicate) experiment (n=3) and expressing the variability for each group (10% EVERGREEN™, 100% EVERGREEN™ stimulated) as a percentage of the variability for the mock (control) stimulated group, which results in an approximately 100% increase in variability without EVERGREEN™ (at both the 10% and 100% levels).
[0221] Example 17. Neuronal survival after freezing / thawing is more consistent using the cryopreservation solution of the present invention than using conventional cryopreservation solutions.
[0222] The cryopreservation solution of the present invention, EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; EVERLAST™ resulted in significantly higher and more consistent neuronal survival rates after freezing / thawing compared to the conventional cryopreservation solution, DMSO (FIG. 17). Mouse primary hippocampal neurons were frozen using EVERGREEN™ vehicle solution compared to dimethyl sulfoxide (DMSO), and survival rates after thawing were measured and plotted. Five independent experiments were measured.
[0223] Example 18. Consistency of neuronal cell viability after freeze-thaw with the cryopreservation solution of the present invention compared to conventional cryopreservation solutions.
[0224] The cryopreservation solution of the present invention, EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase; EVERLAST™ provided significant consistency in neuronal survival after freezing / thawing compared to the traditional cryopreservation solution, DMSO (FIG. 18). The percent variation was calculated by calculating the mean value (n=5) of each experiment and expressing the individual measurements of each group as a ratio to the mean value of the individual values. From this, the percent deviation was calculated and expressed as a percentage of the mean, which represents an approximately 300% increase in variability when the EVERGREEN™ vehicle solution is not used.
[0225] Example 19. Using the cryopreservation solution of the present invention, neuronal activity was maintained even after freezing and thawing.
[0226] The effect of freeze-thawing in the cryopreservation solution of the present invention, EVERGREEN™ vehicle solution: 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-a-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz Units manganese superoxide dismutase; EVERLAST™, was investigated on neuronal activity.
[0227] Briefly, hippocampal neurons were either immediately after dissection (pre) or frozen with Evergreen medium and thawed after 48–72 h (post) and placed in culture in vitro. Neuronal cultures after 17–19 days in vitro were placed in a recording chamber on a Zeiss Axiozoom stage and washed with standard recording media. Neurons were recorded with patch clamp pipettes containing 130 mM K-gluconate, pH 7.3, 10 mM KCl, 0.1 mM EGTA, 5 mM NaCl, 10 mM HEPES, 0.3 mM sodium GTP, and 5 mM phosphocreatine, 1 mM Mg-ATP (range 5–10 MΩ resistance). Signals were amplified with an AxoPatch 200A / AxoClamp2 amplifier and recorded with a pClamp8.
[0228] FIG. 19A shows hippocampal neurons from mouse brains immediately after dissection, and whole-cell current clamp (at resting membrane potential) recordings show network activity in culture. Vertical bars represent 20 millivolt (mV) magnitudes, and horizontal bars represent 2 seconds (s) of recording. FIG. 19B shows hippocampal neurons from mouse brains immediately after dissection after freeze / thaw using EVERGREEN™ vehicle solution, and whole-cell current clamp (at resting membrane potential) recordings show network activity in culture. Vertical bars represent 20 millivolt (mV) magnitudes, and horizontal bars represent 2 seconds (s) of recording. FIG. 19C shows cumulative frequency over a 5-minute recording interval of current clamp data showing the average frequency of action potential discharges. Values are the mean + SE (standard error) of at least four independent experiments, and are not statistically significantly different (p>0.7, Student's t-test) either before or after freeze / thaw using EVERGREEN™ vehicle solution.
[0229] FIG. 19D shows hippocampal neurons from mouse brain immediately after dissection, and whole-cell voltage clamp (at about 60 mV) recordings show network activity in culture. Vertical bars represent 200 picoamps (pA) magnitude, and horizontal bars represent 2 seconds (s) of recording. FIG. 19E shows hippocampal neurons from mouse brain immediately after dissection after freeze / thaw using EVERGREEN™ vehicle solution, and whole-cell voltage clamp (at about 60 mV) recordings show network activity in culture. Vertical bars represent 200 picoamps (pA) magnitude, and horizontal bars represent 2 seconds (s) of recording. FIG. 19F shows cumulative frequency over a 5-minute recording interval of voltage clamp data showing the average frequency of action potential discharges. Values are the mean + SE (standard error) of at least four independent experiments, and there is no statistically significant difference (p>0.8) either before or after freeze / thaw using EVERGREEN™ vehicle solution.
[0230] Figure 19G shows evoked presynaptic action potentials (lower trace) and postsynaptic excitatory synaptic responses (upper trace) shown in current clamp mode at resting potential (shown on the left of the schematic as black circles at the end of the axon from the lower presynaptic neuron) from two adjacent coupled hippocampal neurons both before (left trace, immediately after dissection) and after (right trace) freeze / thaw using EVERGREEN™ vehicle solution. Here, excitatory postsynaptic currents (EPSCs) are not statistically different between treatments (actual values, 71+ / -23 pA before, vs. 76+ / -28 pA after). Representative traces from n=19-22 neurons, at least three independent experiments for each treatment (p>0.7, Student's t-test). Vertical bars represent the magnitude of 20 picoamps (pA) of current-clamped neurons (presynaptic, lower trace) and 20 millivolts (mV) of excitatory synaptic responses (postsynaptic, upper trace), and horizontal bars represent 20 milliseconds (ms) of recording. Figure 19H shows the amplitude ratio of presynaptic (pre / post) evoked action potentials to postsynaptic responses of 19 hippocampal neurons (measured in part G) both before (closed circles) and after (open circles) freeze / thaw using EVERGREEN™ vehicle solution. The mean ratios of neurons before and after freeze / thaw using EVERGREEN™ vehicle solution are not statistically different (p>0.7, Student's t-test) (mean value of 71+ / -23 pA before freeze / thaw vs. mean value of 76+ / -28 pA after freeze / thaw). X-values correspond to the number of neurons for each treatment.
[0231] Thus, hippocampal neurons exhibit indistinguishable physiological properties before (immediately after dissection) and after freezing / thawing using Evergreen medium solution. Patch clamp of neurons at embryonic days 17-19 shows current and voltage profiles from both spontaneous and evoked neuronal activity.
[0232] The foregoing description of specific embodiments fully reveals the general nature of the present invention, so that others, by applying current knowledge, can easily modify and / or adapt to various uses of such specific embodiments without undue experimentation and without departing from the general concept. Such adaptations and modifications should therefore be understood and are intended to be within the meaning and range of equivalents of the disclosed embodiments. It should be understood that the expressions or terms used herein are for purposes of description and not limitation. The means, materials, and steps for carrying out the various disclosed functions may take various alternative forms without departing from the present invention.
Claims
1. A caspase-independent cryopreservation composition for preserving one or more cells, tissues, organs or organisms during cryopreservation, freeze-thaw cycles or cooling cycles, comprising a necroptosis inhibitor compound and a Bax channel inhibitor compound, wherein the necroptosis inhibitor compound has a concentration of 0.2 nM to 10 μM and the Bax channel inhibitor compound has a concentration of 0.5 nM to 50 μM; (a) the necroptosis inhibitor compound is selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compounds, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, and pharma- ceutically acceptable salts of any of these; and (b) the Bax channel inhibitor compound is selected from the group consisting of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol compounds, and pharma- ceutically acceptable salts thereof; A caspase-independent cryopreservation composition, wherein the composition further comprises nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or superoxide dismutase, or any combination thereof.
2. The caspase-independent cryopreservation composition of claim 1 , wherein the superoxide dismutase comprises manganese superoxide dismutase or zinc superoxide dismutase.
3. 0.2 nM to 10 μM of a necroptosis inhibitor selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compounds, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compounds, and 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds.
3. The caspase-independent cryopreservation composition of claim 1 or 2, comprising an inhibitor compound, 0.5 nM to 50 μM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol, 5 nM to 500 μM nicotinamide adenine dinucleotide (NAD), 10 nM to 1 mM adenosine triphosphate (ATP), 1 nM to 1 mM cyclosporine A, and 0.001 KU to 100 KU manganese superoxide dismutase or zinc superoxide dismutase. Claim 4: A necroptosis inhibitor compound at 20 nM to 8 μM, the necroptosis inhibitor compound being selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin, and 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxy- 4. The caspase-independent cryopreservation composition of claim 3, comprising a necroptosis inhibitor compound comprising ethanone, 5 nM to 20 μM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
5. 4. The caspase-independent cryopreservation composition of claim 3, comprising 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
6. The caspase-independent cryopreservation composition of any one of claims 1 to 5, further comprising a cryoprotectant.
7. 7. The caspase-independent cryopreservation composition of claim 6, wherein the cryoprotectant comprises DMSO, or serum, or any combination thereof.
8. The caspase-independent cryopreservation composition of any one of claims 1 to 7, further comprising a pharma- ceutically acceptable excipient or carrier.
9. 1. A method of cryopreservation comprising the steps of: (a) contacting a plurality of cells with a caspase-independent cryopreservation composition comprising 0.2 nM to 10 μM of a necroptosis inhibitor compound and 0.5 nM to 50 μM of a Bax channel inhibitor compound; (b) cooling the composition comprising the plurality of cells of step (a); (i) the necroptosis inhibitor compound is selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compounds, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, and pharma- ceutically acceptable salts of any of these; (ii) the Bax channel inhibitor is selected from the group consisting of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol compounds, and pharma- ceutically acceptable salts thereof; (iii) the composition further comprises nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporine A, or superoxide dismutase, or any combination thereof; (iv) the cooling comprises freeze-thaw cycles; method.
10. The caspase-independent cryopreservation composition according to claim 1, wherein the caspase-independent cryopreservation composition comprises 0.2 nM to 10 μM of a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, a 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compound, a 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compound, 10. The method of claim 9, comprising a necroptosis inhibitor compound selected from the group consisting of: 0.5 nM to 50 μM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol, 5 nM to 500 μM nicotinamide adenine dinucleotide (NAD), 10 nM to 1 mM adenosine triphosphate (ATP), 1 nM to 1 mM cyclosporine A, and 0.001 KU to 100 KU manganese superoxide dismutase or zinc superoxide dismutase.
11. The caspase-independent cryopreservation composition of claim 10, wherein the caspase-independent cryopreservation composition comprises 20 nM to 8 μM of a necroptosis inhibitor compound, the necroptosis inhibitor compound being 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin, or 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]inda 10. The method of claim 9, comprising a necroptosis inhibitor compound comprising 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride at 5 nM to 20 μM, nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
12. 11. The method of claim 10, wherein the caspase-independent cryopreservation composition comprises 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, 5 nM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 KU manganese superoxide dismutase or zinc superoxide dismutase.
13. 1. A method of treating, preventing, inhibiting, or reducing the occurrence of cellular plasticity, or necroptosis or necrosis in a plurality of cells, the method comprising contacting the plurality of cells with a caspase-independent cryopreservation composition comprising 0.2 nM to 10 μM of a necroptosis inhibitor compound and 0.5 nM to 50 μM of a Bax channel inhibitor compound; (i) the necroptosis inhibitor compound is selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compounds, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, and pharma- ceutically acceptable salts of any of these; and (ii) the Bax channel inhibitor is selected from the group consisting of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol compounds, and pharma- ceutically acceptable salts thereof; The method, wherein the composition further comprises nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporin A, or superoxide dismutase, or any combination thereof.
14. The caspase-independent cryopreservation composition comprises 0.2 nM to 10 μM of a 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, a 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compound, a 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compound.
14. The method of claim 13, comprising a necroptosis inhibitor compound selected from the group consisting of: 0.5 nM to 50 μM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride; 5 nM to 500 μM nicotinamide adenine dinucleotide (NAD); 10 nM to 1 mM adenosine triphosphate (ATP); 1 nM to 1 mM cyclosporine A; and 0.001 KU to 100 KU manganese superoxide dismutase or zinc superoxide dismutase.
15. The caspase-independent cryopreservation composition of claim 1, wherein the caspase-independent cryopreservation composition comprises 20 nM to 8 μM of a necroptosis inhibitor compound, the necroptosis inhibitor compound being 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin, or 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazoline.
15. The method of claim 14, comprising a necroptosis inhibitor compound comprising 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride at 5 nM to 20 μM, nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
16. 15. The method of claim 14, wherein the caspase-independent cryopreservation composition comprises 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
17. The method of any one of claims 13 to 16, wherein the necroptosis or necrosis is associated with aging or disease.
18. 18. The method of claim 17, wherein the disease is myocardial infarction, diabetes secondary to beta cell necroptosis, cholestatic liver disease, stroke, organ ischemia, ischemia-reperfusion injury, liver disease, necrosis due to cancer chemotherapy or radiotherapy, traumatic brain injury, necrotizing pancreatitis, pathogen-induced necroptosis, inflammation, or a neurodegenerative disease.
19. 19. The method of any one of claims 13 to 18, wherein said treating, preventing, inhibiting or reducing the occurrence of cellular plasticity, or necroptosis or necrosis comprises treating, preventing, inhibiting or reducing the occurrence of cellular plasticity, necroptosis or necrosis in vitro or in vivo or ex vivo.
20. 20. The method of any one of claims 13 to 19, wherein the plurality of cells comprises tissue culture cells, primary cells, egg cells, tissue, or an organ or part thereof, or any combination thereof.
21. 21. The method of claim 20, wherein the tissue culture or primary cells comprise stem cells, adult cells, transdifferentiated cells, de-differentiated cells, or differentiated cells, or any combination thereof.
22. The method of any one of claims 13 to 21, wherein the plurality of cells comprises human or animal cells.
23. The method of any one of claims 13 to 22, wherein the contacting is in vivo, ex vivo, or in vitro.
24. 24. The method of claim 23, wherein said contacting in vivo or ex vivo comprises perfusion of an animal or a portion thereof, an organ or a portion thereof, or a tissue.
25. 25. The method of claim 24, wherein the perfusion is cardiac perfusion.
26. 24. The method of claim 23, wherein contacting in vitro comprises immersing the plurality of cells in the composition, supplementing growth medium of the plurality of cells with the composition, perfusing the plurality of cells with the composition by non-thermal reversible electroporation, or perfusing the plurality of cells with the composition in a bioreactor.
27. The method of any one of claims 13 to 26, further comprising the step of physical, chemical or thermodynamic manipulation of said plurality of cells.
28. 28. The method of claim 27, wherein the thermodynamic manipulation comprises heating or cooling the plurality of cells.
29. 29. The method of claim 28, wherein the cooling comprises cryopreservation or freeze-thaw cycles, or a combination thereof.
30. 30. The method of any one of claims 13-16 and 20-29, wherein the method prevents, inhibits, or reduces necrosis or necroptic death of the plurality of cells during the cryopreservation or freeze-thaw cycles thereof compared to non-contacted plurality of cells.
31. 31. The method of any one of claims 13-16 and 20-30, wherein said method protects said plurality of cells from physical damage during said cryopreservation or freeze-thaw cycles thereof.
32. 32. The method of any one of claims 13-16 and 20-31, wherein the method enhances the proliferative potential of the plurality of cells during cryopreservation as compared to non-contacted cells.
33. 33. The method of any one of claims 13-16 and 20-32, wherein the method prevents oxidative damage to the plurality of cells during cryopreservation or freeze-thaw cycles thereof.
34. The method of any one of claims 13 to 16 and 20 to 33, wherein said method prevents ischemia of said cells during cryopreservation or freeze-thaw cycles thereof.
35. The method of any one of claims 13 to 34, wherein said method inhibits necrosis pathway signaling.
36. 36. The method of any one of claims 13 to 35, wherein the method prevents, inhibits or reduces a change in the differentiation state of the cell, thereby stabilizing the identity of the cell compared to a non-contacted cell.
37. The method of any one of claims 13 to 36, wherein said method induces a state of metabolic arrest in said cells.
38. 38. The method of claim 37, wherein the metabolic arrest comprises a reversible cessation of oxygen metabolism.
39. 39. The method of any one of claims 13 to 38, wherein the method improves the viability or potential viability of the cells compared to non-contacted cells.
40. The method of any one of claims 13 to 39, wherein the composition further comprises a cryoprotectant.
41. 41. The method of claim 40, wherein the cryoprotectant comprises DMSO, or serum, or any combination thereof.
42. The method of any one of claims 13 to 41, wherein the composition further comprises a pharma- ceutically acceptable carrier or excipient.
43. A composition for use in preventing excessive necrotic and necroptotic cell death, comprising an inhibitor of at least one damage associated molecular pattern (DAMP) that induces necrosis or necroptosis to prevent excessive necrotic and necroptotic cell death during cryopreservation, freeze-thaw cycles, or cooling cycles, or a combination thereof, comprising a caspase-independent cryopreservation composition comprising 0.2 nM to 10 μM of a necroptosis inhibitor compound and 0.5 nM to 50 μM of a Bax channel inhibitor compound; (a) the necroptosis inhibitor is selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compounds, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compounds, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compounds, and pharma- ceutically acceptable salts of any of these; and (b) the Bax channel inhibitor compound is selected from the group consisting of 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol compounds, and pharma- ceutically acceptable salts thereof; The composition further comprises nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), cyclosporin A, or superoxide dismutase, or any combination thereof.
44. 0.2 nM to 10 μM of a compound selected from the group consisting of 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione compound, 5-(indol-3-ylmethyl)-(2-thio-methyl)hydantoin compound, 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-hydroxyethanone compound.
44. The composition of claim 43, comprising a necroptosis inhibitor compound comprising 0.5 nM to 50 μM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol, 5 nM to 500 μM nicotinamide adenine dinucleotide (NAD), 10 nM to 1 mM adenosine triphosphate (ATP), 1 nM to 1 mM cyclosporine A, and 0.001 KU to 100 KU manganese superoxide dismutase or zinc superoxide dismutase.
45. A necroptosis inhibitor compound at 20 nM to 8 μM, comprising 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione, 5-(indol-3-ylmethyl)-(2-thiomethyl)hydantoin, or 1-([3S,3aS]-3-[3-fluoro-4-[trifluoromethoxy]phenyl]-8-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazol-2-yl)-2-methyl-2,4-imidazolidinedione.
45. The composition of claim 44, comprising a necroptosis inhibitor compound comprising -hydroxyethanone, 5 nM to 20 μM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
46. 45. The composition of claim 44, wherein the caspase-independent cryopreservation composition comprises 20 nM 5-((7-chloro-1H-indol-3-yl)methyl)-3-methyl-2,4-imidazolidinedione), 5 nM 3,6-dibromo-α-(1-piperazinylmethyl)-9H-carbazole-9-ethanol dihydrochloride, 0.05 mM nicotinamide adenine dinucleotide (NAD), 0.01 μM adenosine triphosphate (ATP), 0.01 μM cyclosporine A, and 0.1 Kunitz units of manganese superoxide dismutase or zinc superoxide dismutase.
47. 47. The composition of any one of claims 43 to 46, wherein said inhibitor of necrosis or necroptosis inducing DAMPs further comprises an antibody, a protein, a peptide, a small molecule or any combination thereof.
48. 48. The composition of any one of claims 43-47, wherein the DAMP comprises a lipoxygenase inhibitor, a sphingomyelinase inhibitor, a phospholipase inhibitor, a ceramidase inhibitor, a pattern recognition receptor (PRR) ligand, a toll-like receptor (TLR) ligand, a retinoic acid-inducible gene I-like receptor (RIG-I-like) receptor (RLR) ligand, a nucleotide binding domain and leucine-rich repeat-containing molecule (NLR) ligand, a C-type lectin receptor (CLR) ligand, or a death receptor ligand.
49. 49. The composition of claim 48, wherein the ligand comprises high mobility group box 1 protein (HMGB1), heat shock protein (HSP), ribonucleoprotein (RNP), messenger ribonucleic acid (mRNA), high mobility group nucleosome binding domain 1 (HMGN1), hyaluronic acid, biglycan, heparin sulfate, U1 small nucleolar ribonucleoprotein (snRNP), mitochondrial DNA, or double-stranded RNA (dsRNA).
50. 49. The composition of claim 48, wherein the death receptor comprises tumor necrosis factor receptor 1 (TNFR1), tumor necrosis factor receptor 2 (TNFR2), CD95 / FAS receptor, TNF-related apoptosis-inducing ligand receptor 1 (TRAILR1), and TRAILR2.
51. 49. The composition of claim 48, wherein the death receptor ligand comprises a deubiquitinase, a FAS-related protein with a death domain (FADD), a riboflavin kinase (RFK), a tumor necrosis factor, a TNFR2, a FAS ligand (FASL or CD95L), and a TNFR-associated death domain (TRADD).
52. 52. The composition of claim 51 , wherein the deubiquitinases include A20 (TNFAIP3), OTUD7b, cylindromatosis (cylD) and USP21.
53. 53. The composition of any one of claims 43-52, further comprising at least one pharma- ceutically acceptable excipient or carrier, wherein the at least one pharma- ceutically acceptable excipient or carrier comprises a pH stabilizer, a sugar, an amino acid, or an antibiotic, or any combination thereof.
Citation Information
Patent Citations
9-(piperazinylalkyl)carbazoles as bax modifiers
JP2003512371A
Methods and compositions for promoting axon regeneration and nerve function
JP2014530881A
